SARM1 inhibitors and uses thereof
Compounds inhibiting SARM1 NADase activity address neurodegeneration in various neurological disorders by modulating SARM1 activity, offering therapeutic benefits for conditions like ALS, Parkinson's disease, and others.
Patent Information
- Application Number
- PCT/US2026/027417
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for neurological disorders such as ALS, Parkinson's disease, multiple sclerosis, CIPN, TBI, stroke, glaucoma, Charcot-Marie Tooth disease, and dementia-related disorders are inadequate in addressing neurodegeneration and cell death due to the lack of effective inhibitors for the SARM1 NADase activity.
Development of compounds that inhibit SARM1 NADase activity, including pharmaceutically acceptable salts and solvates, which can be administered to modulate SARM1 activity and treat associated diseases.
The compounds effectively suppress neurodegeneration and cell death, providing therapeutic benefits for a range of neurological disorders by targeting SARM1 activity.
Smart Images

Figure US2026027417_12112026_PF_FP_ABST
Abstract
Description
PATENT Attorney Docket No.: 058107-513001WQ SARM1 INHIBITORS AND USES THEREOFCROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U. S. Provisional Application No. 63 / 803,328, filed May 9, 2025, which is incorporated herein by reference in its entirety and for all purposes.BACKGROUND
[0002] The mitochondria associated multidomain Sterile Alpha and TIR motif containing 1 (SARM1) protein is recognized as a metabolic sensor and key regulator of neurodegeneration and cell death. After neuronal injury, increased intracellular NMN / NAD+ratios release SARM1 from an autoinhibited state which results in rapid NAD+depletion via intrinsic TIR-domain based NADase activity. SARM1 is highly expressed across both the central and peripheral nervous system and given the critical role of SARM1 in neuronal loss, inhibitors of SARM1 NADase activity provide a means to suppress neurodegeneration in a variety of neurological disorders including Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, multiple sclerosis, chemotherapy-induced peripheral neuropathies (CIPN), traumatic brain injury (TBI). stroke, glaucoma, Charcot-Marie Tooth disease, and dementia-related disorders. Disclosed herein, inter alia, are solutions to these and other problems in the art.BRIEF SUMMARY
[0003] In an aspect is provided a compound, or a pharmaceutically acceptable salt or solvate thereof, having the formula:
[0005] R1is independently halogen, -CX13, -CHX12, -CH2X1, -OCX's, -OCH2X1, -OCHX, -CN, -SOn1R1D, -SOv1NR1AR1B, -NR1CC(O)NR1AR1B, -N(O)m1, -NR1AR1B.-C(O)NR1AR1B, -OR1D, -SR1D, -NR1ASO2R1D, -NR1AC(O)R1C, -NR1AC(O)OR1C, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0006] The symbol zl is an integer from 0 to 6.
[0007] R2is hy drogen, halogen, -CX23, -CHX22, -CH2X2, -OCX23, -OCH2X2. -OCHX22, -CN, -SOn2R2D, -SOV2NR2AR2B, -NR2CC(O)NR2AR2B, -N(O)m2, -NR2AR2B, -C(O)NR2AR2B. -OR2D, -SR2D, -NR2ASO2R2D, -NR2AC(O)R2C, -NR2AC(O)OR2C, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl.
[0008] R3, R4, and R5are independently hydrogen, halogen, -CC13, -CBr3, -CF3, -CI3, -CHCI2, -CHBr2. -CHF2. -CHI2, -CH2Cl, -CH2Br. -CH2F. -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCI2, -OCHBr2, -OCHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -CN, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NO2, -NH2, -C(O)H, -C(O)OH, -CONH2, -OH, -SH, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -SF5, -N3. substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl.
[0009] R6and R7are independently hydrogen, -CC13, -CBr3, -CF3, -CI3, -CH2CI, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2CI, -OCH2Br, -OCH2F, -OCH2I. -OCHCI2, -OCHBr2. -OCHF2. -OCHh, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; R6and R7substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl.
[0010] R1A, R1B, R1C, R1D, R2A, R2B, R2C, and R2Dare independently hydrogen, -CCl3, -CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -0CH2I, -OCHCI2, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; R1Aand R1Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2Aand R2Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
[0011] Each X1and X2is independently -F, -Cl, -Br, or -I. The sy mbols nl and n2 are independently an integer from 0 to 4. The symbols ml. m2, vl, and v2 are independently 1 or 2.
[0012] In an aspect is provided a pharmaceutical composition including a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0013] In an aspect is provided a method of treating a SARMl-associated disease in a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt of solvate thereof.
[0014] In an aspect is provided a method of modulating SARM1 activity in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt of solvate thereof.DETAILED DESCRIPTIONI. Definitions
[0015] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency know n in the chemical arts.
[0016] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents thatwould result from writing the structure from right to left, e.g., -CH2O- is equivalent to -OCH2-.
[0017] The term "alkyl.” by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di-, and multivalent radicals. The alkyl may include a designated number of carbons (e.g., C1-C10 means one to ten carbons). In embodiments, the alkyl is fully saturated. In embodiments, the alkyl is monounsaturated. In embodiments, the alkyl is polyunsaturated. Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-buty l, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-). An alkyl moiety may be an alkenyl moiety. An alkyl moiety may be an alkynyl moiety. An alkenyl includes one or more double bonds. An alkynyl includes one or more triple bonds.
[0018] The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A “lower alkyd” or “lower alkylene” is a shorter chain alkyd or alkylene group, generally having eight or fewer carbon atoms. The term “alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. The term “alkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyne. In embodiments, the alkylene is fully saturated. In embodiments, the alkylene is monounsaturated. In embodiments, the alky dene is polyunsaturated. An alkenylene includes one or more double bonds. An alkynylene includes one or more triple bonds.
[0019] The term “heteroalkyl,” by itself or in combination with another term, means, unless otherw ise stated, a stable straight or branched chain, or combinations thereof, including atleast one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3,-CH2-CH2-N(CH3)-CH3. -CH2-S-CH2-CH3. -S-CH2-CH3. -S(O)-CH3. -CH2-CH2-S(O)2-CH3.-CH=CH-O-CHS, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -0-CH3,-O-CH2-CH3, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g.. O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety' may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). The term “heteroalkenyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond. A heteroalkenyl may optionally include more than one double bond and / or one or more triple bonds in additional to the one or more double bonds. The term “heteroalkynyl.” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one triple bond. A heteroalkynyl may optionally include more than one triple bond and / or one or more double bonds in additional to the one or more triple bonds. In embodiments, the heteroalkyl is fully saturated. In embodiments, the heteroalkyl is monounsaturated. In embodiments, the heteroalkyl is polyunsaturated.
[0020] Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyd, as exemplified, but not limited by, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g.. alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in w hich the formula of the linking group is written. For example, the formula -C(O)2R'- represents both -C(O)2R'- and -R'C(O)2-. As described above, heteroalkyl groups.as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(O)R', -C(O)NR', -NR'R", -OR', -SR', and / or -SO2R'. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like. The term “heteroalkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkene. The term “heteroalkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkyne. In embodiments, the heteroalkylene is fully saturated. In embodiments, the heteroalkylene is monounsaturated. In embodiments, the heteroalkylene is polyunsaturated. A heteroalkenylene includes one or more double bonds. A heteroalkynylene includes one or more triple bonds.
[0021] The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1 -cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyL 2-piperidinyl, 3-piperidinyl, 4-morpholinyL 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. In embodiments, the cycloalkyl is fully saturated. In embodiments, the cycloalkyl is monounsaturated. In embodiments, the cycloalkyl is polyunsaturated. In embodiments, the heterocycloalkyd is fully saturated. In embodiments, the heterocycloalkyl is monounsaturated. In embodiments, the heterocycloalkyl is polyunsaturated.
[0022] In embodiments, the term “cycloalkyl” means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system. In embodiments, monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturatedor unsaturated, but not aromatic. In embodiments, cycloalkyl groups are fully saturated. A bicyclic or multi cyclic cycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkyl ring of the multiple rings.
[0023] In embodiments, a cycloalkyl is a cycloalkenyl. The term “cycloalkenyl” is used in accordance with its plain ordinary meaning. In embodiments, a cycloalkenyl is a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system. A bicyclic or multicyclic cycloalkenyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkenyl ring and wherein the multiple rings are attached to the parent molecular moiety- through any carbon atom contained within a cycloalkenyl ring of the multiple rings.
[0024] In embodiments, the term “heterocycloalkyl” means a monocyclic, bicyclic, or a multicyclic heterocycloalkyl ring system. In embodiments, heterocycloalkyl groups are fully saturated. A bicyclic or multicyclic heterocycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a heterocycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heterocycloalkyl ring of the multiple rings.
[0025] The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalky 1 and polyhaloalkyl. For example, the term “haJo(Ci-C4)alkyl” includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0026] The term “acyl” means, unless otherwise stated, -C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0027] The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an and ringand wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within an aryl ring of the multiple rings. The term “heteroaryl” refers to ar l groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heteroaromatic ring of the multiple rings). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl. benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1 -naphthyl, 2 -naphthyl. 4-biphenyl, 1 -pyrrolyl. 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-fuiyl, 2-thienyl, 3-thienyl, 2 -pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl. 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1 -isoquinolyl, 5-isoquinolyl, 2-quinoxalinyL 5 -quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “ary lene'’ and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.
[0028] Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may havedifferent substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g., substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g., all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
[0029] Bridged rings are two or more rings that share three or more atoms, separating the two bridgehead atoms by a bridge containing at least one atom. Individual rings in bridged rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of bridged rings. Possible substituents for individual rings within bridged rings are the possible substituents for the same ring when not part of bridged rings (e.g., substituents for cycloalkyl or heterocycloalkyl rings). Bridged rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a bridged ring group may be any of the immediately previous list, including having all rings of one type (e.g., all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a bndged ring system, heterocyclic bridged rings means bridged rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a bridged ring system, substituted bridged rings means that at least one ring is substituted and each substituent may optionally be different.
[0030] The symbol ” denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.
[0031] The term '‘oxo,’’ as used herein, means an oxygen that is double bonded to a carbon atom.
[0032] The term “alkylarylene” as an ary lene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:
[0033] An alkylary lene moiety' may be substituted (e.g., with a substituent group) on the alkylene moiety or the arylene linker (e.g., at carbons 2. 3, 4, or 6) with halogen, oxo, -N3, -CF3. -CCl3, -CBr3, -CI3. -CN. -CHO, -OH, -NH2. -COOH. -CONH2. -NO2, -SH. -SO2CH3, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, substituted or unsubstituted C1-C5 alkyl, or substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, the alkylarylene is unsubstituted.
[0034] Each of the above terms (e.g., “alkyl,” “heteroalkyl.” “cycloalkyl.” “heterocycloalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
[0035] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl. cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =0, =NR', =N-0R', -NR'R", -SR', halogen, -SiR'R" R'", -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR" C(O)R', -NR'C(0)NR" R"', -NR" C(O)2R'. -NRC(NR'R" R'")=NR"". -NRC(NR'R")=NR"', -S(O)R', -S(O)2R’, -S(O)2NR'R", -NRSO2R', -NR'NR" R"', -ONR'R", -NR'C(O)NR" NR'" R"", -CN, -NO2, -NR’SO2R", -NR'C(O)R", -NR'C(O)OR", -NR'OR", in a number ranging from zero to (2m'+l), where m' is the total number of carbon atoms in such radical. R, R', R", R'", and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R'. R". R'", and R"" group when more than one of these groups is present. When R' and R" are attached to the samenitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" includes, but is not limited to, 1 -pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, and the like).
[0036] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', halogen, -SiR'R" R"', -OC(O)R', -C(O)R', -CO2R’, -CONR'R", -OC(O)NR'R", -NR" C(O)R', -NR'C(O)NR" R"', -NR" C(O)2R’, -NR-C(NR'R" R'")=NR"", -NR-C(NR'R")=NR'", -S(O)R', -S(O)2R'. -S(O)2NR'R", -NRSO2R', -NR'NR'R"', -ONR'R", -NR'C(O)NR" NR"'R"". -CN, -NO2, -R', -N3, -CH(Ph)2, fluoro(Ci-C4)alkoxy, and fluoro(Ci-C4)alkyl, -NR'SO2R", -NR'C(O)R", -NR'C(O)OR", -NR'OR", in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R'", and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alky l, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R"" groups when more than one of these groups is present.
[0037] Substituents for rings (e.g.. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a moleculeis not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e g., a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
[0038] Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ringforming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.
[0039] Two of the substituents on adjacent atoms of the ary l or heteroaryl ring may optionally form a ring of the formula -T-C(O)-(CRR')q-U-, wherein T and U are independently -NR-, -O-, -CRR'-, or a single bond, and q is an integer of from 0 to 3.Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR')s-X'-(C" R" R'")d-, w here s and d are independently integers of from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituents R, R', R", and R'" arepreferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0040] As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
[0041] A “substituent group,” as used herein, means a group selected from the following moieties:(A) oxo, halogen, -CC13, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2CL -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHC12, -OCHBr2, -OCHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H. -OSO3H, -SO2NH2, -NHNH2, -0NH2, -NHC(O)NHNH2, -NHC(0)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(0)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., Ci-Cs alkyl, Ci-Ce alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-Cs cycloalkyl, C3-Ce cycloalkyl, or Cs-Ce cycloalkyl), unsubstituted heterocycloalkyl (e g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., Ce-Cw aryl, C10 ar 1, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered heteroary l. 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), and / or(B) alkyl (e.g., Ci-Cs alkyl, Ci-Ce alkyl, or C1-C4 alkyl), heteroalkyl (e.g., 2 to 8 membered heteroalkyd, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalky l), cycloalkyl (e.g., C3-Cs cy cloalkyl, C3-Ce cycloalky 1, or C5-C6 cycloalkyl), heterocycloalkyl (e.g.. 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), aryl (e.g., Ce-Cio aryl, C10 aryl, or phenyl), heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroary l), substituted wi th at least one substituent selected from:(i) oxo, halogen, -CCl3, -CBr3, -CF3. -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCb, -OCHBr2,-0CHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -CN, -OH, -NH2.-COOH, -CONH2, -NO2. -SH, -SO3H. -OSO3H. -SO2NH2, -NHNH2. -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., Ci-Cs alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl. 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C -C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., Ce-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), and / or (ii) alkyl (e.g., Ci-Cs alkyl, Ci-Ce alkyl, or C1-C4 alkyl), heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or Cs-Ce cycloalkyl), heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), aryl (e.g., Ce-C10 aryl, C10 aryl, or phenyl), heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), substituted with at least one substituent selected from:(a) oxo. halogen. -CCI3, -CBr3. -CF3, -Cl3. -CHCk, -CHBr2. -CHF2. -CH12.-CH2CI, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr, -OCI3, -OCHCl2, -OCHBr2, -OCHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I, -OCH2F, -CN, -OH, -NH2. -COOH, -CONH2. -NO2, -SH. -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e g., Ci-Cs alkyl, Ci-Ce alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl. 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e g., Cs-Cs cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., Ce-Cio aryl, C10 aryl, or phenyl), orunsubstituted heteroaryl (e.g., 5 to 10 membered heteroaryl. 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl), and / or(b) alkyl (e.g., Ci-Cs alkyl. Ci-Cs alkyl, or C1-C4 alkyl), heteroalkyl (e.g.. 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyd), cycloalkyl (e.g., C3-C8 cycloalky l, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), aryl (e.g., Ce- C10 aryl, C10 aryl, or phenyl), heteroaryl (e.g., 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroary 1), substituted with at least one substituent selected from: oxo, halogen, -CCI3, -CB, -CF3, -CI3, -CHCI2, -CHBr2, -CHF2, -CHI2. -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3. -OCI3, -OCHCl2. -OCHBr2, -OCHI2. -OCHF2. -OCH2Cl, -OCH2Br. -OCH2I, -OCH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -0NH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., Ci-Cs alkyl, Ci-Ce alkyl, or C1-C4 alkyl), unsubstituted heteroalkyd (e.g., 2 to 8 membered heteroalkyd, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalky 1), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyd), unsubstituted heterocycloalkyd (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyd), unsubstituted aryl (e g., Ce-Cio aryl, C10 aryl, or phenyl), or unsubstituted heteroary! (e.g., 5 to 10 membered heteroaryl. 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
[0042] A “size-limited substituent” or “ size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalky l, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted ary l is a substituted or unsubstituted Ce-Cio aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
[0043] A “lower substituent"’ or “ lower substituent group,’" as used herein, means a group selected from all of the substituents described above for a “substituent group.” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted phenyl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 6 membered heteroaryl.
[0044] In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkydene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
[0045] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted O,-C10 aryl, and / or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C20 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted ary lene is a substituted or unsubstituted Ce-Cio arylene, and / or each substitutedor unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
[0046] In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted Ce-Cio aryl, and / or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted Ci-Cs alkydene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalky dene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene, each substituted or unsubstituted heterocycloalkydene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted Ce-Cio arylene, and / or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section or tables below.
[0047] In embodiments, a substituted or unsubstituted moiety' (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyd, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted ary l, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and / or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted ary l, substituted or unsubstituted heteroaryl, substituted or unsubstitutedalky lene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene, respectively).
[0048] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent group, wherein if the substituted moiety is substituted with a plural i ty of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
[0049] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one size-limited substituent group, wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety' is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
[0050] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one lower substituent group, wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group is different.
[0051] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, if the substituted moiety7is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group is different.
[0052] In a recited claim or chemical formula description herein, each R substituent or L linker that is described as being “substituted” without reference as to the identity7of any chemical moiety that composes the “substituted” group (also referred to herein as an “open substitution” on an R substituent or L linker or an “openly substituted” R substituent or L linker), the recited R substituent or L linker may, in embodiments, be substituted with one or more first substituent groups as defined below.
[0053] The first substituent group is denoted with a corresponding first decimal point numbering system such that, for example, R1may be substituted with one or more first substituent groups denoted by R1 1, R2may be substituted with one or more first substituent groups denoted by R2 1, R3may be substituted with one or more first substituent groups denoted by R3 1, R4may be substituted with one or more first substituent groups denoted by R4R5may be substituted with one or more first substituent groups denoted by R5 1, and the like up to or exceeding an R100that may be substituted with one or more first substituent groups denoted by R100 1. As a further example, R1Amay be substituted with one or more first substituent groups denoted by R1A 1, R2Amay be substituted with one or more first substituent groups denoted by R2A I. R3Amay be substituted w ith one or more first substituent groups denoted by R3A A, R4Amay be substituted with one or more first substituent groups denoted by R4A1, R5Amay be substituted with one or more first substituent groups denoted by R5A 1and the like up to or exceeding an R100Amay be substituted with one or more first substituent groups denoted by R100A-1. As a further example, L1may be substituted with oneor more first substituent groups denoted by RLL1, L2may be substituted with one or more first substituent groups denoted by RL2L3may be substituted with one or more first substituent groups denoted by R.1'3 1. L4may be substituted with one or more first substituent groups denoted by RL4 1, L5may be substituted with one or more first substituent groups denoted by RL5 1and the like up to or exceeding an L100which may be substituted with one or more first substituent groups denoted by RL100 1. Thus, each numbered R group or L group (alternatively referred to herein as Rwwor Lwwwherein " WW" represents the stated superscript number of the subject R group or L group) described herein may be substituted with one or more first substituent groups referred to herein generally as Rww 1or RLWW 1, respectively. In turn, each first substituent group (e g., R1R21, R3’, R41, R5 1... R100R1A 1. R2A 1, R3A 1, R4A1, R5A 1... R100A 1; RL1 1, RL21, RL3 1, RL41, RL5 1... RL100 1) may be further substituted with one or more second substituent groups (e.g., R1 2, R22, R3 2, R42, R5.2 OO 2. IA.2 2A.2 3A.2 4A.2 5A.2 LOOA.2. L1.2 L2.2 L3.2 L4.2 L5 2 RLIOO2, respectively). Thus, each first substituent group, which may alternatively be represented herein as Rw w 1as described above, may be further substituted with one or more second substituent groups, which may alternatively be represented herein as Rvw-2
[0054] Finally, each second substituent group (e g., R1 2, R22, R3 2, R42, R52... R100'2; R1A-2R2A'2,R3A.2R4A2R5A.2R100A.2.RL12RL2.2,RL3.2,RL4.2,RL5.2RL100.2)MAY BE FURTHERsubstituted with one or more third substituent groups (e g., R1 3, R23, R3 3, R43, R5 3... R1003;R1A.3R2A.3R3A.3 R A.3R5A.3R100A.3.RL1.3 RL2.3RL3.3 RL4.3RL5 3RL100.3. respectively). Thus, each second substituent group, which may alternatively be represented herein as RWW 2as described above, may be further substituted with one or more third substituent groups, which may alternatively be represented herein as RWW 3. Each of the first substituent groups may be optionally different. Each of the second substituent groups may be optionally different. Each of the third substituent groups may be optionally different.
[0055] Thus, as used herein, Rwwrepresents a substituent recited in a claim or chemical formula description herein which is openly substituted. “WW” represents the stated superscript number of the subject R group (1, 2, 3, 1A, 2A, 3A, IB, 2B, 3B, etc.). Likewise, Lwwis a linker recited in a claim or chemical formula description herein which is openly substituted. Again, " WW” represents the stated superscript number of the subject L group (1, 2, 3, 1A, 2A, 3A, IB, 2B, 3B, etc ). As stated above, in embodiments, each Rwwmay be unsubstituted or independently substituted with one or more first substituent groups, referredto herein as Rww leach first substituent group, Rwwmay be unsubstituted or independently substituted with one or more second substituent groups, referred to herein as Rww-2; and each second substituent group may be unsubstituted or independently substituted with one or more third substituent groups, referred to herein as RWVl-3. Similarly, each Lwwlinker may be unsubstituted or independently substituted with one or more first substituent groups, referred to herein as RLWW-1; each first substituent group, RLWWmay be unsubstituted or independently substituted with one or more second substituent groups, referred to herein as J^LWW.2.eac seconcj substituent group may be unsubstituted or independently substituted with one or more third substituent groups, referred to herein as RLW W 3. Each first substituent group is optionally different. Each second substituent group is optionally different. Each third substituent group is optionally different. For example, if Rwxis phenyl, the said phenyl group is optionally substituted by one or more Rww 1groups as defined herein below, e.g., when Rww 1is RWW 2-substituted or unsubstituted alkyl, examples of groups so formed include but are not limited to itself optionally substituted by 1 or more Rww-2, which Rww 2is optionally substituted by one or more Rww-3. By way of example when the Rw wgroup is phenyl substituted by Rwwwhich is methyl, the methyl group may be further substituted to form groups including but not limited to:unsubstituted alkyl (e.g., Ci-Cs, Ci-Cg, C1-C4, or C1-C2), Rww^-substituted or unsubstituted heteroalkyl (e.g.. 2 to 8 membered, 2 to 6 membered, 4 to 6 membered. 2 to 3 membered, or 4 to 5 membered), Rww^-substituted or unsubstituted cycloalkyd (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), Rww 2-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), Rww^-substituted or unsubstituted aryl (e.g., Cg-Ci2, Cg-Cio, or phenyl), or Rww’-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RWW 1is independently7oxo, halogen, -CXWW 13, -CHXWW-12, -CH2XWW-1, -OCXWWk, -0CH2XWW-1, -OCHXWW’2, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH. -SO3H. -OSO3H. -SO2NH2, -NHNH2. -0NH2, -NHC(0)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g., Ci-Cs, Ci-Cg, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., Cs-Cs, C3-C6. C4-C6, or Cs-Cg), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., Cg-Ci2, Cg-Cio, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). xww 1is independently -F, -Cl, -Br, or -I.
[0057] RWW-2is independently oxo, halogen, -CXWW 23. -CHXWW 22, -CH2XWW 2.-OCXWW 23, -OCH2XWW 2, -OCHXWW 22, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, NHNH2, 0NH2, NHC(0)NHNH2, NHC(0)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(0)H, -NHC(0)0H, -NHOH, -N3. Rww’-substituted or unsubstituted alkyl (e.g.. Ci-Cs, Ci-Cg, C1-C4. or C1-C2), RWW 3-substituted or unsubstituted heteroalkyl (e g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RWW 3-substituted or unsubstituted cycloalkyl (e.g., C3-C8, Cs-Cg, C4-C, or Cs-Cg), Rww’-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered. 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), Rww’-substituted or unsubstituted aryl (e.g., Cg-Ci2, Cg-Cio, or phenyl), or Rww’-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RWW 2is independently oxo, halogen, -CXWW 23, -CHXWW 22, -CH2XWW 2, -OCXWW 23, -0CH2XWW 2, -OCHXWW 22, -CN, -OH, -NH2, -COOH, -C0NH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(0)0H, -NHOH, -N3,unsubstituted alkyl (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered. 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted ary l (e.g., C6-C12, Ce-Cio, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). xWW 2is independently -F, -CL -Br, or -1.
[0058] Rww 3is independently oxo, halogen, -CX 'V'-3?. -CHXW W 32, -CH2XV, W 3, -OCXWW 33, -OCH2XWW 3, -OCHXWW 32, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -0NH2, -NHC(0)NHNH2, -NHC(0)NH2, -NHC(NH)NH2. -NHSO2H. -NHC(0)H, -NHC(0)0H. -NHOH, -N3, unsubstituted alkyl (e g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), unsubstituted heteroalkyd (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalky l (e g., Cs-Cs, C3-C6, C4-C6, or Cs-Ce), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered. 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, Cg-Cio, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). xWW 3is independently -F, -Cl, -Br, or -I.
[0059] Where two different Rwwsubstituents are joined together to form an openly substituted ring (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl or substituted heteroaryl), in embodiments the openly substituted ring may be independently substituted with one or more first substituent groups, referred to herein as RWW 1; each first substituent group, RWW 1, may be unsubstituted or independently substituted with one or more second substituent groups, referred to herein as Rww-2; and each second substituent group, RWW.2,mayunsubstituted or independently substituted with one or more third substituent groups, referred to herein as Rww-3; and each third substituent group, Rww'3, is unsubstituted. Each first substituent group is optionally different. Each second substituent group is optionally different. Each third substituent group is optionally different. In the context of two different Rwwsubstituents joined together to form an openly substituted ring, the " WW” symbol in the RWWJ, Rww-2and RWW.3refers 10the designated number of one of the two different Rwwsubstituents. For example, in embodiments where R100Aand R100Bare optionally joined together to form an openly substituted ring, Rww 1is R100A 1, RWW-2-SR100A2, and RW W 3is R100A 3Alternatively, in embodiments where R100Aand R100Bare optionally joined together to form an openly substituted ring, RWW 1is R100B 1, RWW-2jsR100B 2, and RWW 3is R100B 3paragraph are as defined in the preceding paragraphs.
[0060] RLWW 1is independently oxo, halogen, -CXLWW 13, -CHXLWW 12, -CH2XLWW-1, -OCXLWW-OCH2XLWW 1, -OCHXLWW-CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H. -OSO3H. -SO2NH2, -NHNH2. -0NH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -Ns, RLWW^-substituted or unsubstituted alkyd (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), RLWW 2-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RLWW^-substituted or unsubstituted cycloalkyl (e.g.. C3-C8, C3-C6, C4-C6. or Cs-Cg), RLWW 2-substituted or unsubstituted heterocycloalkyl (e g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RLWW 2-substituted or unsubstituted aryl (e.g., C6-C12, Ce-Cio, or phenyl), or RLWW^-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RLWW 1is independently oxo, halogen, -CXLW, W 13, -CHXLWW 12, -CH2XLWW-1, -OCXLWW'13, -OCH2XLWW-1, -OCHXLWW'12, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -0NH2, -NHC(O)NHNH2. -NHC(O)NH2. -NHC(NH)NH2, -NHSO2H. -NHC(O)H, -NHC(O)OH. -NHOH, -N3, unsubstituted alkyd (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), unsubstituted heteroalkyd (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyd (e.g., Cs-Cs, C3-C6, C4-C6, or Cs-Ce). unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered. 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, Cs-Cio, or phenyl), or unsubstituted heteroaryd (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XLWW 1is independently -F, -Cl, -Br, or -I.
[0061] RLWW 2isindependently oxo, halogen, -CXLWW 23, -CHXLWW 22. -CH2XLWW 2. -OCXLWW 23. -OCH2XLWW 2. -OCHXLWW 22. -CN, -OH, -NH2. -COOH, -CONH2. -NO2, -SH.unsubstituted alkyl (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), RLWW 3-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4to 5 membered), Rww^’-substituted or unsubstituted cycloalkyl (e.g., Cs-Cs. C3-C6, C-i-Ce, or Cs-Ce). RLWW 3-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), R1" " '-substituted or unsubstituted aryl (e.g., Cg-Ci2, Cg-Cio, or phenyl), or R, w'-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RLWW 2is independently oxo, halogen, -CXLWW 23, -CHXLWW 22. -CH2XLWW 2. -OCXLWW 23. -OCH2XLWW 2. -0CHXLWW 22. -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2. -NHC(NH)NH2, -NHSO2H. -NHC(O)H, -NHC(O)OH. -NHOH, -N3, unsubstituted alkyl (e.g., Ci-Cs, Ci-Cg, C1-C4, or C1-C2), unsubstituted heteroalkyl (e g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., Ce-Ci2, Cg-Cio, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). xLWW 2is independently -F, -Cl, -Br, or -I.
[0062] RLWW 3is independently oxo, halogen, -CXLWW 33, -CHXLWW 32, -CH2XLWW 3, -OCX1 WW 33, -OCH2XLWW3, -0CHX1 WW32, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH. -SO3H. -OSO3H. -SO2NH2, -NHNH2. -ONH2, -NHC(O)NHNH2, -NHC(O)NH2.-NHC(NH)NH2, -NHSO2H, -NHC(0)H, -NHC(0)0H, -NHOH, -N3, unsubstituted alkyl (e.g., Ci-Cs, Ci-Ce, C1-C4, or Ci-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6. C4-C6, or Cs-Cg), unsubstituted heterocycloalkyl (e.g.. 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted ary l (e.g., Cg-Ci2, Cg-Cio, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). xLWW 3is independently -F, -Cl, -Br, or -I.
[0063] In the event that any R group recited in a claim or chemical formula description set forth herein (Rwwsubstituent) is not specifically defined in this disclosure, then that R group (R"" group) is hereby defined as independently oxo, halogen, -CXWW3, -CHXWW2, -CH2XWW, -OCXWW3, -0CH2XWW, -0CHXWW2, -CN. -OH, -NH2, -COOH. -C0NH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -0NH2, -NHC(0)NHNH2, -NHC(0)NH2,-NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3. Rww 1-substituted or unsubstituted alkyl (e.g.. Ci-Cs, Ci-Ce, C1-C4. or C1-C2), Rww 1-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RWW 1-substituted or unsubstituted cycloalkyl (e.g., Cs-Cs, C3-C6, C4-C6, or Cs-Ce), Rww^-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RWW 1-substituted or unsubstituted aryl (e.g., C6-C12, Ce-Cio, or phenyl), or RWW 1-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). xwwis independently F, -Cl, -Br, or -I. Again, “WW” represents the stated superscript number of the subject R group (e.g., 1, 2, 3, 1 A, 2A, 3A, IB, 2B, 3B, etc.).RW 1,RWW anjRWW-3are asdefined above.
[0064] In the event that any L linker group recited in a claim or chemical formula description set forth herein (i.e., an Lw wsubstituent) is not explicitly defined, then that L group (Lwwgroup) is herein defined as independently a bond, O-, -NH-, -C(O)-, -C(0)NH-, -NHC(O)-, -NHC(0)NH-, -NHC(NH)NH-, -C(O)O-, -OC(O)-, -S-, -SO2-, -SO2NH-, RLWW 1-substituted or unsubstituted alkylene (e.g.. Ci-Cs, Ci-Ce, C1-C4. or C1-C2), RL 1-substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RLWW 1-substituted or unsubstituted cycloalkyd ene (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), RLWW 1-substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered. 4 to 5 membered, or 5 to 6 membered), RL^ i-substituted or unsubstituted arylene (e.g., C6-C12, Cs-Cio, or phenyl), or RLWW 1-substituted or unsubstituted heteroarylene (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). Again, “WW” represents the stated superscript number of the subject L group (1, 2, 3, 1A, 2A, 3A, IB, 2B, 3B, etc.). RLWW 1,as well as RLW W 2and RLWW.3are asdefine(jabove.
[0065] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry’, as (R)-or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and / or isolate. The present disclosure is meant to include compounds in racemic and optically pureforms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
[0066] As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
[0067] The term “tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
[0068] It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.
[0069] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
[0070] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by13C- or14C-enriched carbon are within the scope of this disclosure.
[0071] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( H). iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
[0072] It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possibleamino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.
[0073] As used herein, the terms “bioconjugate” and “bioconjugate linker” refer to the resulting association between atoms or molecules of bioconjugate reactive groups or bioconjugate reactive moieties. The association can be direct or indirect. For example, a conjugate between a first bioconjugate reactive group (e.g., -NH2, -COOH, -N-hydroxy succinimide, or -mal eimide) and a second bioconjugate reactive group (e.g., sulfhydry l, sulfur-containing amino acid, amine, amine sidechain containing amino acid, or carboxylate) provided herein can be direct, e.g., by covalent bond or linker (e.g., a first linker of second linker), or indirect, e.g., by non-covalent bond (e.g., electrostatic interactions (e.g., ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g., dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like). In embodiments, bioconjugates or bioconjugate linkers are formed using bioconjugate chemistry' (i.e.. the association of two bioconjugate reactive groups) including, but are not limited to nucleophilic substitutions (e.g.. reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition). These and other useful reactions are discussed in, for example, March. ADVANCED ORGANIC CHEMISTRY, 3rd Ed., John Wiley & Sons. New York, 1985; Hermanson, BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and Feeney et al., MODIFICATION OF PROTEINS; Advances in Chemistry Series, Vol. 198, American Chemical Society7, Washington, D. C., 1982. In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety7) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., haloacetyl moiety ) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., pyridyl moiety) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., -N-hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., an amine). In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl).In embodiments, the first bioconjugate reactive group (e.g., -sulfo-N-hydroxy succinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., an amine).
[0074] Useful bioconjugate reactive moieties used for bioconjugate chemistries herein include, for example: (a) carboxyl groups and various derivatives thereof including, but not limited to, N-hydroxysuccinimide esters, N-hydroxybenztri azole esters, acid halides, acyl imidazoles, thioesters, p-nitrophenyl esters, alkyl, alkenyl, alkynyl and aromatic esters; (b) hydroxyl groups which can be converted to esters, ethers, aldehydes, etc.; (c) haloalkyl groups wherein the halide can be later displaced with a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion, thereby resulting in the covalent attachment of a new group at the site of the halogen atom; (d) dienophile groups which are capable of participating in Diels-Alder reactions such as, for example, maleimido or maleimide groups; (e) aldehyde or ketone groups such that subsequent derivatization is possible via formation of carbonyl derivatives such as, for example, imines, hydrazones, semicarbazones or oximes, or via such mechanisms as Grignard addition or alkyllithium addition; (f) sulfonyl halide groups for subsequent reaction with amines, for example, to form sulfonamides; (g) thiol groups, which can be converted to disulfides, reacted with acyl halides, or bonded to metals such as gold, or react with maleimides; (h) amine or sulfhydryl groups (e.g., present in cysteine), which can be, for example, acylated, alky lated or oxidized; (i) alkenes, which can undergo, for example, cycloadditions, acylation, Michael addition, etc.; (j) epoxides, which can react with, for example, amines and hydroxyl compounds; (k) phosphoramidites and other standard functional groups useful in nucleic acid synthesis; (1) metal silicon oxide bonding; (m) metal bonding to reactive phosphorus groups (e.g., phosphines) to form, for example, phosphate diester bonds; (n) azides coupled to alkynes using copper catalyzed cycloaddition click chemistry; and (o) biotin conjugate can react with avidin or streptavidin to form an avidinbiotin complex or streptavidin-biotin complex.
[0075] The bioconjugate reactive groups can be chosen such that they do not participate in, or interfere with, the chemical stability' of the conjugate described herein. Alternatively, a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group. In embodiments, the bioconjugate comprises a molecular entity' derived from the reaction of an unsaturated bond, such as a maleimide, and a sulfhydryl group.
[0076] “Analog,"’ “analogue,” or “derivative” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
[0077] The terms “a” or “an”, as used in herein means one or more. In addition, the phrase “substituted with a[n]”, as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is "substituted with an unsubstituted C1-C20 alkyl, or unsubstituted 2 to 20 membered heteroalkyl”, the group may contain one or more unsubstituted C1-C20 alkyds, and / or one or more unsubstituted 2 to 20 membered heteroalkyds.
[0078] Moreover, where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R13substituents are present, each R13substituent may be distinguished as R13 A, R13 D. R13 C. R13 D, etc., wherein each of R13 A, R13 B, R13 c. R13 D. etc. is defined within the scope of the definition of R13and optionally differently.
[0079] Descriptions of compounds of the present disclosure are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and / or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
[0080] The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al.. “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977. 66. 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0081] Thus, the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids. The present disclosure includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary' ammonium salts (e.g., methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.
[0082] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. Theparent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0083] In addition to salt forms, the present disclosure provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Prodrugs of the compounds described herein may be converted in vivo after administration. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.
[0084] Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
[0085] A polypeptide, or a cell is “recombinant"’ when it is artificial or engineered, or derived from or contains an artificial or engineered protein or nucleic acid (e.g., non-natural or not wild type). For example, a polynucleotide that is inserted into a vector or any other heterologous location, e.g.. in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a recombinant polynucleotide. A protein expressed in vitro or in vivo from a recombinant polynucleotide is an example of a recombinant polypeptide. Likewise, a polynucleotide sequence that does not appear in nature, for example a variant of a naturally occurring gene, is recombinant.
[0086] A “cell"’ as used herein, refers to a cell carry ing out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaroytic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they arenaturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
[0087] The terms “treating” or “treatment” refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and / or a psychiatric evaluation. For example, the certain methods presented herein successfully treat cancer by decreasing the incidence of cancer and or causing remission of cancer. In some embodiments of the compositions or methods described herein, treating cancer includes slowing the rate of growth or spread of cancer cells, reducing metastasis, or reducing the growth of metastatic tumors. The term “treating” and conjugations thereof, include prevention of an injury', pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing. In embodiments, the treating or treatment is not prophylactic treatment.
[0088] An “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce signaling pathway, reduce one or more symptoms of a disease or condition. An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount” when referred to in this context. A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity' or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effectiveamount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. An “activity increasing amount,” as used herein, refers to an amount of agonist required to increase the activity of an enzyme relative to the absence of the agonist. A “function increasing amount,” as used herein, refers to the amount of agonist required to increase the function of an enzyme or protein relative to the absence of the agonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3. 1992); Lloyd, The Art. Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
[0089] “Control” or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity (e.g.. signaling pathway) of a protein in the absence of a compound as described herein (including embodiments, examples, or Tables).
[0090] “Contacting” is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g., chemical compounds including biomolecules, or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.
[0091] The term “contacting” may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a cellular component (e.g.. protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, virus, lipid droplet, vesicle, small molecule, protein complex, protein aggregate, or macromolecule). In some embodimentscontacting includes allowing a compound described herein to interact with a cellular component (e.g., protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, virus, lipid droplet, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule) that is involved in a signaling pathway.
[0092] As defined herein, the term “activation,’' “activate,’' “activating” and the like in reference to a protein refers to conversion of a protein into a biologically active derivative from an initial inactive or deactivated state. The terms reference activation, or activating, sensitizing, or up-regulating signal transduction or enzy matic activity7or the amount of a protein decreased in a disease.
[0093] The terms “agonist,” “activator,” “upregulator,” etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% in comparison to a control in the absence of the agonist. In certain instances, expression or activity7is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
[0094] As defined herein, the term “inhibition,” “inhibit,” “inhibiting” and the like in reference to a cellular component-inhibitor interaction means negatively affecting (e.g., decreasing) the activity' or function of the cellular component (e.g., decreasing the signaling pathway stimulated by a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)), relative to the activity' or function of the cellular component in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g., decreasing) the concentration or levels of the cellular component relative to the concentration or level of the cellular component in the absence of the inhibitor. In some embodiments, inhibition refers to reduction of a disease or symptoms of disease. In some embodiments, inhibition refers to a reduction in the activity' of a signal transduction pathway or signaling pathway (e.g., reduction of a pathway involving the cellular component). Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating the signaling pathway or enzymatic activity or the amount of a cellular component.
[0095] The terms "inhibitor." ‘‘repressor,’' “antagonist,” or “downregulator” interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold. 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
[0096] The term “modulator” refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule (e.g., a target may be a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)) relative to the absence of the composition.
[0097] The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
[0098] The term “modulate” is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
[0099] “Patient”, “subject”, “patient in need thereof’, or “subject in need thereof’ refers to a living organism suffering from or prone to a disease or condition that can be treated by¬ administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In embodiments, a patient is human. In embodiments, a subject is human. In embodiments, a patient in need thereof is human. In embodiments, a subject in need thereof is human.
[0100] “Disease"’ or “condition’" refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. In some embodiments, the disease is a disease related to (e.g., caused by) a cellular component (e.g., protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule). In embodiments, the disease is a neurodegenerative disease. In embodiments, the disease is an inflammatory disease. In embodiments, the disease is multiple sclerosis. In embodiments, the disease is a cancer.
[0101] As used herein, the term “neurodegenerative disease” refers to a disease or condition in which the function of a subject's nervous system becomes impaired. Examples of neurodegenerative diseases that may be treated with a compound, pharmaceutical composition, or method described herein include Alexander’s disease, Alper’s disease, Alzheimer’s disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia. Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington’s disease, HIV-associated dementia, Kennedy’s disease, Krabbe’s disease, kuru, Lewy body dementia, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple sclerosis, Multiple System Atrophy, Narcolepsy, Neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick’s disease, Primary lateral sclerosis, Prion diseases, Refsum’s disease, Sandhoff’s disease, Schilder’s disease. Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Schizophrenia, Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, or Tabes dorsalis.
[0102] As used herein, the term “inflammatory disease” refers to a disease or condition characterized by aberrant inflammation (e.g., an increased level of inflammation compared to a control such as a healthy person not suffering from a disease). Examples of inflammatory diseases include autoimmune diseases, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet’sdisease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison’s disease, Vitiligo, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, scleroderma, and atopic dermatitis.
[0103] As used herein, the term “autoimmune disease” refers to a disease or condition in which a subject’s immune system has an aberrant immune response against a substance that does not normally elicit an immune response in a healthy subject. Examples of autoimmune diseases that may be treated with a compound, pharmaceutical composition, or method described herein include Acute Disseminated Encephalomyelitis (ADEM), Acute necrotizing hemorrhagic leukoencephalitis, Addison’s disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM / Anti-TBM nephritis. Antiphospholipid syndrome (APS), Autoimmune angi oedema, Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune oophoritis. Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease. Autoimmune urticaria, Axonal or neuronal neuropathies, Balo disease, Behcet’s disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac disease, Chagas disease, Chronic fatigue syndrome, Chronic inflammatory demyelinating polyneuropathy (CIDP). Chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome. Cicatricial pemphigoid / benign mucosal pemphigoid, Crohn’s disease, Cogans syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST disease, Essential mixed cryoglobulinemia, Demyelinating neuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic’s disease (neuromyelitis optica), Discoid lupus, Dressier’s syndrome, Endometriosis, Eosinophilic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Experimental allergic encephalomyelitis, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture’s syndrome, Granulomatosis with Polyangiitis (GPA) (formerly called Wegener’s Granulomatosis), Graves’ disease, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis,Interstitial cystitis, Juvenile arthritis. Juvenile diabetes (Type 1 diabetes), Juvenile myositis, Kawasaki syndrome. Lambert-Eaton syndrome. Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus (SLE), Lyme disease, chronic, Meniere’s disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neuromyelitis optica (Devic's). Neutropenia, Ocular cicatricial pemphigoid. Optic neuritis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria (PNH), Party Romberg syndrome, Parsonnag e-Tumer syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome.Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon. Reactive Arthritis, Reflex sympathetic dystrophy, Reiter’s syndrome, Relapsing polychondritis, Restless legs syndrome. Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma. Sjogren's syndrome. Sperm & testicular autoimmunity. Stiff person syndrome, Subacute bacterial endocarditis (SBE), Susac’s syndrome, Sympathetic ophthalmia, Takayasu’s arteritis, Temporal arteritis / Giant cell arteritis. Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Type 1 diabetes, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo, or Wegener’s granulomatosis (i.e.. Granulomatosis with Polyangiitis (GPA).
[0104] As used herein, the term ’‘demyelinating disease” refers to any disease or condition characterized by damage to the protective covering (e.g., myelin sheath) that surrounds nerve fibers (e.g.. in the brain, optic nerves, or spinal cord). In embodiments, the demyelinating disease is a demyelinating disease of the central nervous system. In embodiments, the demyelinating disease is multiple sclerosis. In embodiments, the demyelinating disease is a demyelinating disease of the peripheral nervous system.
[0105] As used herein, the term “eye disease’' refers to a disease or condition characterized by eye problems (e.g., an increased level of eye problems compared to a control such as a healthy person not suffering from a disease). Examples of eye diseases include, but are not limited to, cataract (e.g., congenital cataract), optic nerve disorders (e.g., glaucoma), retinal disorders, macular degeneration, diabetic eye problems, and conjunctivitis.
[0106] As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g., humans), including leukemia, lymphoma, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head and neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, medulloblastoma, colorectal cancer, or pancreatic cancer. Additional examples include, Hodgkin’s Disease, Non-Hodgkin’s Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary' thrombocytosis, primary' macroglobulinemia, primary' brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, esophageal cancer, genitourinary’ tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary' thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
[0107] The term “leukemia” refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embry onal leukemia, eosinophilic leukemia, Gross’ leukemia,hairy -cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling’s leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.
[0108] As used herein, the term “lymphoma” refers to a group of cancers affecting hematopoietic and lymphoid tissues. It begins in lymphocytes, the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow. Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin’s disease. Hodgkin’s disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed-Sternberg malignant B lymphocytes. Non-Hodgkin’ s lymphomas (NHL) can be classified based on the rate at which cancer grows and the t pe of cells involved. There are aggressive (high grade) and indolent (low grade) types of NHL. Based on the type of cells involved, there are B-cell and T-cell NHLs. Exemplary7B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma. Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt’s lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B-lymphoblastic lymphoma. Exemplary' T-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
[0109] The term “sarcoma” generally refers to a tumor which is made up of a substance tike the embry onic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abernethy’s sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma,chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms’ tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen’s sarcoma, Kaposi’s sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.
[0110] The term “melanoma” is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman’s melanoma, S91 melanoma, Harding-Passey melanomajuvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.[OHl] The term “carcinoma” refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatinifomi carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypemephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher’s carcinoma, Kulchitzky-cell carcinoma,large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare. lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, Schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum.
[0112] As used herein, the term “SARMl-associated disease” refers to any disease or condition caused by aberrant activity or signaling of SARM1. In embodiments, the SARMl-associated disease is a neurodegenerative disease. In embodiments, the SARMl-associated disease is an inflammatory disease. In embodiments, the SARMl-associated disease is multiple sclerosis. In embodiments, the SARMl-associated disease is a cancer.
[0113] The term “drug” is used in accordance with its common meaning and refers to a substance which has a physiological effect (e.g.. beneficial effect, is useful for treating a subject) when introduced into or to a subject (e.g., m or on the body of a subject or patient). A drug moiety is a radical of a drug.
[0114] A “detectable agent,” “detectable compound,” “detectable label,” or “detectable moiety ” is a substance (e.g., element), molecule, or composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, magnetic resonance imaging, or other physical means. For example, detectable agents include18F,32P,33P.45Ti,47Sc,52Fe,59Fe,62Cu,64Cu,67Cu,67Ga,68Ga,77As,86Y,90Y,89Sr,89Zr,94Tc,94Tc,99mTc,99Mo,105Pd,223Ra,225Ac, Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce. Pr, Nd. Pm, Sm, Eu, Gd. Tb. Dy, Ho, Er, Tm, Yb, Lu,32P, fluorophore (e.g., fluorescent dyes), modified oligonucleotides (e.g., moieties described in PCT / US2015 / 022063, which is incorporated herein by reference),electron-dense reagents, enzy mes (e.g., as commonly used in an ELISA), biotin, digoxigenin, paramagnetic molecules, paramagnetic nanoparticles, ultrasmall superparamagnetic iron oxide (" USPIO") nanoparticles, USPIO nanoparticle aggregates, superparamagnetic iron oxide (" SPIO") nanoparticles, SPIO nanoparticle aggregates, monochrystalline iron oxide nanoparticles, monochrystalline iron oxide, nanoparticle contrast agents, liposomes or other delivery vehicles containing Gadolinium chelate (" Gd-chelate") molecules. Gadolinium, radioisotopes, radionuclides (e.g., carbon-11, nitrogen-13, oxy gen-15, fluorine-18, rubidium-82), fluorodeoxyglucose (e.g., fluorine-18 labeled), any gamma ray emitting radionuclides, positron-emitting radionuclide, radiolabeled glucose, radiolabeled water, radiolabeled ammonia, biocolloids, microbubbles (e.g., including microbubble shells including albumin, galactose, lipid, and / or polymers; microbubble gas core including air. heavy gas(es). perfluorcarbon, nitrogen, octafluoropropane, perflexane lipid microsphere, perflutren, etc ), iodinated contrast agents (e.g., iohexol, iodixanol, ioversol, iopamidol, ioxilan, iopromide, diatrizoate, metrizoate, ioxaglate), barium sulfate, thorium dioxide, gold, gold nanoparticles, gold nanoparticle aggregates, fluorophores, two-photon fluorophores, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide.
[0115] Radioactive substances (e.g., radioisotopes) that may be used as imaging and / or labeling agents in accordance with the embodiments of the disclosure include, but are not limited to,18F,32P.33P,45Ti,47Sc,52Fe,59Fe,62Cu,64Cu,67Cu,67Ga,68Ga,77As,86Y,90Y,89Sr,89Zr,94TC,94TC,99mTc, " Mo,105Pd,105Rh,niAg,mIn,123L1241,125I,131L142Pr,143Pr,149Pm,153Sm,154 581Gd,161Tb,166Dy,166Ho,169Er,175Lu,177Lu,186Re,188Re,189Re,194Ir,198Au,199Au,211At,211Pb,212Bi,212Pb,213Bi,223Ra and225Ac. Paramagnetic ions that may be used as additional imaging agents in accordance with the embodiments of the disclosure include, but are not limited to, ions of transition and lanthanide metals (e.g., metals having atomic numbers of 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.
[0116] “Pharmaceutically acceptable excipient’' and “pharmaceutically acceptable carrier’" refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactatedRinger's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preser atives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and / or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.
[0117] The term “preparation’' is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
[0118] As used herein, the term “about’' means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to + / - 10% of the specified value. In embodiments, about includes the specified value.
[0119] As used herein, the term “administering” is used in accordance with its plain and ordinary meaning and includes oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g.. buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intraarteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such aschemotherapy, hormonal therapy, radiotherapy, or immunotherapy. The compounds of the invention can be administered alone or can be co-administered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation). The compositions of the present invention can be delivered by transdermally, by atopical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
[0120] The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating a disease associated with cells expressing a disease associated cellular component, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
[0121] In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Coadministration includes administering two active agents simultaneously, approximately simultaneously (e.g.. within about 1. 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and / or adjunctive agents may be linked or conjugated to one another.
[0122] In therapeutic use for the treatment of a disease, compound utilized in the pharmaceutical compositions of the present invention may be administered at the initial dosage of about 0.001 mg / kg to about 1000 mg / kg daily. A daily dose range of about 0.01 mg / kg to about 500 mg / kg, or about 0.1 mg / kg to about 200 mg / kg, or about 1 mg / kg to about 100 mg / kg, or about 10 mg / kg to about 50 mg / kg, can be used. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound or drug being employed. For example, dosages can be empirically determined considering the type and stage of disease (e.g., neurodegenerative disease, inflammatory disease, fibrotic disease, kidney disease, or cancer) diagnosed in a particular patient. The dose administered to a patient, in the context of the present invention, should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dose will also be determined by the existence, nature, and extent of any adverseside effects that accompany the administration of a compound in a particular patient.Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
[0123] The term "associated" or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g., a protein associated disease, disease associated with a cellular component) means that the disease (e.g., neurodegenerative disease, inflammatory7disease, or cancer) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function or the disease or a symptom of the disease may be treated by modulating (e.g., inhibiting or activating) the substance (e.g., cellular component). As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease.
[0124] The term “aberrant” as used herein refers to different from normal. When used to describe enzymatic activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity7may refer to an amount of activity7that results in a disease, wherein returning the aberrant activity7to a normal or non-disease-associated amount (e.g., by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.
[0125] The term “isolated,” when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It can be. for example, in a homogeneous state and may be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified.
[0126] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by thegenetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
[0127] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
[0128] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may in embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[0129] An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there canbe stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.
[0130] The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.
[0131] The term “protein complex” is used in accordance with its plain ordinary meaning and refers to a protein which is associated with an additional substance (e.g., another protein, protein subunit, or a compound). Protein complexes typically have defined quaternary structure. The association between the protein and the additional substance may be a covalent bond. In embodiments, the association between the protein and the additional substance (e.g., compound) is via non-covalent interactions. In embodiments, a protein complex refers to a group of two or more polypeptide chains. Proteins in a protein complex are linked by non-covalent protein-protein interactions. A non-limiting example of a protein complex is the proteasome.
[0132] The term “sterile alpha and TIR motif containing 1” or “SARM1” refers to a protein (including homologs, isoforms, and functional fragments thereof) that in humans is encoded by the SARM1 gene. The term includes any recombinant or naturally-occurring form of SARM1 variants thereof that maintain SARM1 activity (e.g., within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype SARM1). In embodiments, the SARM1 protein encoded by the SARM1 gene has the amino acid sequence set forth in or corresponding to Entrez 23098, UniProt Q6SZW1, or RefSeq (protein) NP_055892.2. In embodiments, the SARM1 gene has the nucleic acid sequence set forth in RefSeq (mRNA) RefSeq (mRNA) NM_015077.4. In embodiments, the amino acid sequence or nucleic acid sequence is the sequence known at the time of filing of the present application.IL Compounds
[0133] In an aspect is provided a compound, or a pharmaceutically acceptable salt or solvate thereof, having the formula:
[0134] Ring A is a heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6membered),
[0135] R1is independently halogen, -CXJ3, -CHX12, -CH2X1, -OCXS. -OCH2X1, -OCHX, -CN, -SOn1R1D, -SOv1NR1AR1B, -NR1CC(O)NR1AR1B, -N(O)m1, -NR1AR1B, -C(O)NR1AR1B, -OR1D, -SR1D. -NR1ASO2R1D. -NR1AC(O)R1C, -NR1AC(O)OR1C, -SF5, -N3. substituted or unsubstituted alkyl (e.g., Ci-Cs, Ci-Ce, C1-C4, or Ci-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce). substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., Ce-Cio or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered. 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., Ce-Cio or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0136] The symbol zl is an integer from 0 to 6.
[0137] R2is hy drogen, halogen, -CX23, -CHX22, -CH2X2, -OCX23, -OCH2X2. -OCHX22, -CN, -SOn2R2D, -SOV2NR2AR2B, -NR2CC(O)NR2AR2B, -N(O)m2, -NR2AR2B, -C(O)NR2AR2B, -OR2D, -SR2D, -NR2ASO2R2D, -NR2AC(O)R2C, -NR2AC(O)OR2C, -SF5, -N3, substituted or unsubstituted alkyd (e.g., Ci-Cs, Ci-Ce, C1-C4, or Ci-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered. 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
[0138] R3, R4, and R5are independently hydrogen, halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCI2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHC12, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -SO3H. -OSO3H. -SO2NH2, -NHNH2. -ONH2, -NHC(0)NHNH2, -NHC(0)NH2, -NO2. -NH2, -C(O)H, -C(O)OH, -CONH2, -OH, -SH, -NHSO2H, -NHC(0)H, -NHC(O)OH, -NHOH, -SF5, -N3, substituted or unsubstituted alky l (e.g., Ci-Cs, Ci-Ce, C1-C4, or Ci-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered. 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, Cs-Ce, C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
[0139] R6and R7are independently hydrogen, -CCl3, -CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCI3. -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I. -OCHC12, -OCHBr2. -OCHF2. -OCHI2, substituted or unsubstituted alkyl (e g., Ci-Cs, Ci-Ce, C1-C4, or Ci-C2), substituted or unsubstituted heteroalkyd (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalky l (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered. 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered): R6and R7substituents bonded to the same nitrogen atom may7optionally be joined to form a substituted or unsubstituted heterocycloalky l (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
[0140] R1A, R1B, R1C, R1D, R2A, R2B. R2C, and R2Dare independently hydrogen. -CCI3, -CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBrs, -OCF3, -OCIs, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHC12, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alky l (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6. C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered); R1Aand R1Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); R2Aand R2Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
[0141] Each X1and X2is independently -F, -Cl, -Br, or -I.
[0142] The symbols nl and n2 are independently an integer from 0 to 4.
[0143] The symbols ml, m2, vl, and v2 are independently 1 or 2.
[0144] In embodiments, the compound has the formula:Ring A is a heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); R1is independently halogen, -CX13, -CHX, -CH2X1,-SF5. -N3, substituted or unsubstituted alkyl (e.g., Ci-Cs, Ci-Ce. C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered. 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered. 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., Ce-Cio or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9membered, or 5 to 6 membered): zl is an integer from 0 to 6; R2is hydrogen, halogen, -CX2s, -CHX22, -CH2X2, -OCX23, -OCH2X2, -OCHX22. -CN. -SOn2R2D, -SOV2NR2AR2B, -NR2CC(O)NR2AR2B, -N(0)m2, -NR2AR2B, -C(O)NR2AR2B, -OR2D, -SR2D, -NR2ASO2R2D, -NR2AC(O)R2C, -NR2AC(O)OR2C, -SF5, -N3, substituted or unsubstituted alky l (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered); R3, R4, and R5are independently hydrogen, halogen, -CCI3, -CBr3, -CF3, -CI3, -CHCI2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3. -OCBr3, -OCI3, -OCHCI2, -OCHBr2, -OCHI2. -OCHF2. -OCH2Cl, -OCH2Br. -OCH2I, -OCH2F, -CN, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NO2, -NH2, -C(O)H, -C(O)OH, -CONH2, -OH, -SH, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -SF5. -N3, substituted or unsubstituted alkyl (e.g.. Ci-Cs, Ci-Ce, Ci-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., Cs-Cs, C3-C6, C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered); R6and R7are independently hydrogen, -CCI3, -CBn. -CF3, -CI3, -CH2CL -CH2Br, -CH2F, -CH2I, -CHCI2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHCl2, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl (e.g., Ci-Cs, Ci-Ce, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered. 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., Cs-Cs, C3-C6, C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyd (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered); R6and R7substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered); R1A, R1B, R1C, R1D, R2A, R2B, R2C, and R2Dare independently hy drogen, -CCl3, -CBr3, -CF3, -CI3, -CH2CI, -CFFBr. -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3. -OCH2Cl, -OCH2Br. -OCH2F.-OCH2I, -OCHCl2, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl (e g., Ci-Cs, Ci-Cg, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., Cs-Cs, C3-C6. C4-C6, or Cs-Ce), or substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered); R1Aand R1Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); R2Aand R2Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); each X1and X2is independently -F, -CL -Br, or -I; nl and n2 are independently an integer from 0 to 4; and ml, m2, vl, and v2 are independently 1 or 2.
[0145] In embodiments, the compound has the formula:Ring A, R1, zl, R2. R3. R4. R5. R6. and R7are as described herein, including in embodiments.
[0146] In embodiments, the compound has the formula:Ring A, R1, zl, R2, R3, R4, R5, R6, and R7are as described herein, including in embodiments.
[0147] In embodiments, the compound has the formula:Ring A, R1, zl, R6, and R7are as described herein, including in embodiments.[014S] In embodiments, the compound has the formula:Ring A, R1, zl. R2, R6, and R7are as described herein, including in embodiments.
[0149] In embodiments, the compound has the formula:Ring A, R1, zl, R3, R6, and R7are as described herein, including in embodiments.
[0150] In embodiments, the compound has the formula:in embodiments.
[0151] In embodiments, the compound has the formula:Ring A, R1, zl, R2, R3, R6, and R7are as described herein, including in embodiments.
[0152] In embodiments, the compound has the formula:including in embodiments.
[0153] In embodiments, the compound has the formula:Ring A, R1. zl. R3, R4, R6, and R7are as described herein. including in embodiments.
[0154] In embodiments, Ring A is a heteroaryl. In embodiments, Ring A is a 5 to 10 membered heteroaryl. In embodiments, Ring A is a 5 or 6 membered heteroaryl. In embodiments, Ring A is a 5 membered heteroaryl. In embodiments, Ring A is a 9 or 10 membered fused ring heteroaryl. In embodiments, Ring A is pyrazolyl. In embodiments, Ring A is imidazolyl. In embodiments. Ring A is triazolyl. In embodiments, Ring A is oxazolyl. In embodiments. Ring A is isoxazolyl. In embodiments, Ring A is oxadiazolyl. In embodiments, Ring A is thiazolyl. In embodiments, Ring A is isothiazolyl. In embodiments, Ring A is thiadiazolyl. In embodiments, Ring A is pyridyl. In embodiments, Ring A is pyridonyl. In embodiments. Ring A is pyrazinyl. In embodiments. Ring A is pyrimidinyl. Inembodiments, Ring A is pyridazinyl. In embodiments, Ring A is triazinyl. In embodiments, Ring A is indazolyl. In embodiments. Ring A is pyrazolopyridinyl. In embodiments, Ring A is pyrrolotriazinyl. In embodiments, Ring A is triazolopyridinyl. In embodiments, Ring A is imidazopyrazinyl. In embodiments, Ring A is pyrazolopyrazinyl. In embodiments, Ring A is purinyl.herein, including in embodiments. In embodiments,in embodiments. In embodiments,embodiments,embodiments,embodiments,embodiments,
[0156] In embodiments, a substituted R1(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R1is substituted, it is substituted with at least one substituent group. In embodiments, when R1is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1is substituted, it is substituted with at least one lower substituent group.
[0157] In embodiments, a substituted ring formed when two R1substituents are joined (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when two R1substituents are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when the substituted ring formed when two R1substituents are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the substituted ring formed when two R1substituents are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the substituted ring formed when two R1substituents are joined is substituted, it is substituted with at least one lower substituent group.
[0158] In embodiments, a substituted R1A(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1Ais substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R1Ais substituted, it is substituted with at least one substituent group. In embodiments, when R1Ais substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1Ais substituted, it is substituted with at least one lower substituent group.
[0159] In embodiments, a substituted R1B(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1Bis substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R1Bis substituted, it is substituted with at least one substituent group. In embodiments, when R1Bis substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1Bis substituted, it is substituted with at least one lower substituent group.
[0160] In embodiments, a substituted ring formed when R1Aand R1Bsubstituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R1Aand R1Bsubstituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when the substituted ring formed when R1Aand R1Bsubstituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the substituted ring formed when R1Aand R1Bsubstituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when thesubstituted ring formed when R1Aand R1Bsubstituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0161] In embodiments, a substituted R1C(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1Cis substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R1Cis substituted, it is substituted with at least one substituent group. In embodiments, when R1Cis substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1Cis substituted, it is substituted with at least one lower substituent group.
[0162] In embodiments, a substituted R1D(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1Dis substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R1Dis substituted, it is substituted with at least one substituent group. In embodiments, when R1Dis substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1Dis substituted, it is substituted with at least one lower substituent group.
[0163] In embodiments, R1Ais independently hydrogen. In embodiments, R1Ais independently unsubstituted C1-C4 alkyl. In embodiments, R1Ais independently unsubstituted methyl. In embodiments, R1Ais independently unsubstituted ethyl. In embodiments, R1Ais independently unsubstituted propyl. In embodiments, R1Ais independently unsubstituted n-propyl. In embodiments, R1Ais independently unsubstituted isopropyl. In embodiments, R1Ais independently unsubstituted butyl. In embodiments, R1Ais independently unsubstituted n-butyl. In embodiments, R1Ais independently unsubstituted isobutyl. In embodiments. R1Ais independently unsubstituted tert-butyl.
[0164] In embodiments, R1Bis independently hydrogen. In embodiments, R1Bis independently unsubstituted C1-C4 alkyl. In embodiments, R1Bis independentlyunsubstituted methyl. In embodiments, R1Bis independently unsubstituted ethyl. In embodiments, R1Bis independently unsubstituted propyl. In embodiments. R1Bis independently unsubstituted n-propyl. In embodiments, R1Bis independently unsubstituted isopropyl. In embodiments, R1Bis independently unsubstituted butyl. In embodiments, R1Bis independently unsubstituted n-butyl. In embodiments, R1Bis independently unsubstituted isobutyl. In embodiments. R1Bis independently unsubstituted tert-butyl.
[0165] In embodiments, R1Cis independently hydrogen. In embodiments, R1Cis independently unsubstituted C1-C4 alkyl. In embodiments, R1Cis independently unsubstituted methyl. In embodiments, R1Cis independently unsubstituted ethyl. In embodiments, R1Cis independently unsubstituted propyl. In embodiments, R1Cis independently unsubstituted n-propyl. In embodiments, R1Cis independently unsubstituted isopropyl. In embodiments, R1Cis independently unsubstituted butyl. In embodiments, R1Cis independently unsubstituted n-butyl. In embodiments, R1Cis independently unsubstituted isobutyl. In embodiments, R1Cis independently unsubstituted tert-butyl.
[0166] In embodiments, R1Dis independently hydrogen. In embodiments, R1Dis independently unsubstituted C1-C4 alkyl. In embodiments, R1Dis independently unsubstituted methyl. In embodiments, R1Dis independently unsubstituted ethyl. In embodiments, R1Dis independently unsubstituted propyl. In embodiments, R1Dis independently unsubstituted n-propyl. In embodiments, R1Dis independently unsubstituted isopropyl. In embodiments, R1Dis independently unsubstituted butyl. In embodiments, R1Dis independently unsubstituted n-butyl. In embodiments, R1Dis independently unsubstituted isobutyl. In embodiments, R1Dis independently unsubstituted tert-butyl.
[0167] In embodiments, R1is independently halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2CI, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCl2, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I. -OCH2F. -CN, -SO3H. -OSO3H, -SO2NH2, -NHC(O)NH2, -NO2, -NH2, -CONH2, -OH, -SH, -NHSO2H, -NHC(O)H, -NHC(O)OH, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0168] In embodiments, R1is independently halogen. In embodiments, R1is independently -F. In embodiments, R1is independently -Cl. In embodiments, R1is independently -Br. In embodiments, R1is independently -I. In embodiments, R1is independently -CCh. In embodiments, R1is independently -CBn. In embodiments, R1is independently -CF3. In embodiments, R1is independently -CI3. In embodiments, R1is independently -CH2Cl, In embodiments, R1is independently -CH2Br. In embodiments, R1is independently -CH2F. In embodiments, R1is independently -CH2I. In embodiments, R1is independently -CHX12. In embodiments, R1is independently -CHCI2. In embodiments, R1is independently -CHBr2. In embodiments, R1is independently -CHF2. In embodiments, R1is independently -CHI2. In embodiments, R1is independently -CN. In embodiments, R1is independently -OR1D. In embodiments, R1is independently -OH. In embodiments, R1is independently -NH2. In embodiments, R1is independently -C(O)NR1AR1B. In embodiments, R1is independently -CONH2. In embodiments, R1is independently -NO2. In embodiments, R1is independently -SH. In embodiments, R1is independently -SO3H. In embodiments, R1is independently -OSO3H. In embodiments, R1is independently -SO2NH2. In embodiments, R1is independently -ONH2. In embodiments, R1is independently -NHC(O)NH2. In embodiments, R1is independently -NHSO2H. In embodiments, R1is independently -NHC(O)H. In embodiments, R1is independently -NHC(O)OH. In embodiments, R1is independently -OCCh. In embodiments, R1is independently -OCB. In embodiments, R1is independently -OCF3. In embodiments, R1is independently -OCI3. In embodiments, R1is independently -OCH2CI. In embodiments, R1is independently -OCH2Br. In embodiments, R1is independently -OCH2F. In embodiments, R1is independently -OCH2I. In embodiments, R1is independently -OCHCl2. In embodiments, R1is independently -OCHBr2. In embodiments, R1is independently -OCHF2. In embodiments, R1is independently -OCHI2. In embodiments, R1is independently -SF5. In embodiments, R1is independently -N3. In embodiments, R1is independently unsubstituted C1-C4 alkyl. In embodiments, R1is independently unsubstituted methyl. In embodiments, R1is independently unsubstituted ethyl. In embodiments, R1is independently unsubstituted propyl. In embodiments, R1is independently unsubstituted n-propyl. In embodiments, R1is independently unsubstituted isopropyl. In embodiments, R1is independently unsubstituted butyl. In embodiments, R1is independently unsubstituted n-butyl. In embodiments, R1is independently unsubstituted isobutyl. In embodiments. R1is independently unsubstituted tert-butyl. In embodiments, R1is independently unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1isindependently unsubstituted methoxy. In embodiments, R1is independently unsubstituted ethoxy. In embodiments, R1is independently unsubstituted propoxy. In embodiments, R1is independently unsubstituted n-propoxy. In embodiments, R1is independently unsubstituted isopropoxy. In embodiments, R1is independently unsubstituted butoxy. In embodiments, R1is independently unsubstituted C3-C8 cycloalkyl. In embodiments, R1is independently unsubstituted cyclopropyl. In embodiments, R1is independently unsubstituted cyclobutyl. In embodiments, R1is independently unsubstituted cyclopentyl. In embodiments, R1is independently unsubstituted cyclohexyl. In embodiments, R1is independently unsubstituted cycloheptyl. In embodiments, R1is independently unsubstituted cyclooctyl.
[0169] In embodiments, R1is independently halogen, -CHX, -CN, -C(O)NR1AR1B, -OR1D, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl. In embodiments, R1is independently -F, -Cl, -CHF2, -CN, -C(O)NH2, -OH, unsubstituted methyl, or unsubstituted cyclopropyl. In embodiments, R1is independently halogen, -CN, or unsubstituted C1-C4 alkyl. In embodiments, R1is independently -F, -Cl, -CN, or unsubstituted methyl.
[0170] A person having ordinary skill in the art would understand that the maximum value of zl will depend on the valency of the cyclic group to which R1is attached. For example,whenthen zl is an integer from 0 to 3.
[0171] In embodiments, zl is 0. In embodiments, z1 is 1. In embodiments, zl is 2. In embodiments, zl is 3. In embodiments, zl is 4. In embodiments, zl is 5. In embodiments, zl is 6.embodiments,In embodiments,
[0173] In embodiments, two R1substituents are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted ary l, or substituted or unsubstituted heteroaryl. In embodiments, two R1substituents are joined to form a substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
[0174] In embodiments,
[0175] In embodiments, a substituted R2(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2is substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R2is substituted, it is substituted with at least one substituent group. In embodiments, when R2is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2is substituted, it is substituted with at least one lower substituent group.
[0176] In embodiments, a substituted R2A(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if thesubstituted R2Ais substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R2Ais substituted, it is substituted with at least one substituent group. In embodiments, when R2Ais substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2Ais substituted, it is substituted with at least one lower substituent group.
[0177] In embodiments, a substituted R2B(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2Bis substituted with a plurality’ of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lo ver substituent group may optionally be different. In embodiments, when R2Bis substituted, it is substituted with at least one substituent group. In embodiments, when R2Bis substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2Bis substituted, it is substituted with at least one lower substituent group.
[0178] In embodiments, a substituted ring formed when R2Aand R2Bsubstituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R2Aand R2Bsubstituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when the substituted ring formed when R2Aand R2Bsubstituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the substituted ring formed when R2Aand R2Bsubstituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the substituted ring formed when R2Aand R2Bsubstituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0179] In embodiments, a substituted R2C(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2Cis substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R2Cis substituted, it is substituted with at least one substituent group. In embodiments, when R2Cis substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2Cis substituted, it is substituted with at least one lower substituent group.
[0180] In embodiments, a substituted R2D(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2Dis substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R2Dis substituted, it is substituted with at least one substituent group. In embodiments, when R2Dis substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2Dis substituted, it is substituted with at least one lower substituent group.
[0181] In embodiments, R2Ais hydrogen. In embodiments. R2Ais unsubstituted C1-C4 alkyl. In embodiments, R2Ais unsubstituted methyl. In embodiments, R2Ais unsubstituted ethyl. In embodiments, R2Ais unsubstituted propyl. In embodiments, R2Ais unsubstituted n-propyl. In embodiments, R2Ais unsubstituted isopropyl. In embodiments, R2Ais unsubstituted butyl. In embodiments, R2Ais unsubstituted n-butyl. In embodiments, R2Ais unsubstituted isobutyl. In embodiments, R2Ais unsubstituted tert-butyl.
[0182] In embodiments, R2Bis hydrogen. In embodiments, R2Bis unsubstituted C1-C4 alkyl. In embodiments, R2Bis unsubstituted methyl. In embodiments, R2Bis unsubstituted ethyl. In embodiments, R2Bis unsubstituted propyl. In embodiments, R2Bis unsubstituted n-propyl. In embodiments, R2Bis unsubstituted isopropyl. In embodiments, R2Bis unsubstituted butyl. In embodiments, R2Bis unsubstituted n-butyl. In embodiments, R2Bis unsubstituted isobutyl. In embodiments, R2Bis unsubstituted tert-butyl.
[0183] In embodiments, R2Cis hydrogen. In embodiments, R2Cis unsubstituted C1-C4 alkyl. In embodiments, R2Cis unsubstituted methyl. In embodiments, R2Cis unsubstituted ethyl. In embodiments, R2Cis unsubstituted propyl. In embodiments, R2Cis unsubstituted n-propyl. In embodiments, R2Cis unsubstituted isopropyl. In embodiments, R2Cis unsubstituted butyl. In embodiments, R2Cis unsubstituted n-butyl. In embodiments, R2Cis unsubstituted isobutyl. In embodiments, R2Cis unsubstituted tert-butyl.
[0184] In embodiments, R2Dis hydrogen. In embodiments, R2Dis unsubstituted C1-C4 alkyl. In embodiments, R2Dis unsubstituted methyl. In embodiments, R2Dis unsubstituted ethyl. In embodiments, R2Dis unsubstituted propyl. In embodiments, R2Dis unsubstituted n-propyl. In embodiments, R2Dis unsubstituted isopropyl. In embodiments, R2Dis unsubstituted butyl. In embodiments, R2Dis unsubstituted n-butyl. In embodiments, R2Dis unsubstituted isobutyl. In embodiments, R2Dis unsubstituted tert-butyl.
[0185] In embodiments, R2is hydrogen, halogen, -CCI3, -CBn, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHC12, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -SO3H, -OSO3H. -SO2NH2, -NHC(O)NH2, -NO2. -NH2, -CONH2, -OH, -SH. -NHSO2H. -NHC(O)H, -NHC(O)OH, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl.
[0186] In embodiments, R2is hydrogen. In embodiments, R2is halogen. In embodiments, R2is -F. In embodiments. R2is -Cl. In embodiments, R2is -Br. In embodiments, R2is -I. In embodiments, R2is -CCI3. In embodiments, R2is -CB. In embodiments, R2is -CF3. In embodiments, R2is -CI3. In embodiments, R2is -CH2C1. In embodiments, R2is -CH2Br. In embodiments, R2is -CH2F. In embodiments, R2is -CH2I. In embodiments, R2is -CHCh. In embodiments, R2is -CHBr2. In embodiments, R2is -CHF2. In embodiments, R2is -CHI2. In embodiments, R2is -CN. In embodiments, R2is -OH. In embodiments, R2is -NH2. In embodiments, R2is -CONH2. In embodiments, R2is -NO2. In embodiments, R2is -SH. In embodiments, R2is -SO3H. In embodiments, R2is -OSO3H. In embodiments, R2is -SO2NH2. In embodiments, R2is -ONH2. In embodiments, R2is -NHC(O)NH2. In embodiments, R2is -NHSO2H. In embodiments, R2is -NHC(O)H. In embodiments, R2is -NHC(O)OH. In embodiments, R2is -OCX23. In embodiments, R2is -OCCI3. In embodiments, R2is -OCB. In embodiments, R2is -OCF3. In embodiments, R2is -OCI3. Inembodiments, R2is -OCH2Cl. In embodiments, R2is -OCH2Br. In embodiments, R2is -OCH2F. In embodiments, R2is -OCH2I. In embodiments, R2is -OCHX22. In embodiments, R2is -OCHCl2. In embodiments, R2is -OCHBr2. In embodiments, R2is -OCHF2. In embodiments, R2is -OCHI2. In embodiments, R2is -SF5. In embodiments, R2is -N3. In embodiments, R2is unsubstituted C1-C4 alkyl. In embodiments, R2is unsubstituted methyl. In embodiments, R2is unsubstituted ethyl. In embodiments, R2is unsubstituted propyl. In embodiments, R2is unsubstituted n-propyl. In embodiments, R2is unsubstituted isopropyl. In embodiments, R2is unsubstituted butyl. In embodiments, R2is unsubstituted n-butyl. In embodiments, R2is unsubstituted isobutyl. In embodiments, R2is unsubstituted tert-butyl. In embodiments, R2is unsubstituted 2 to 6 membered heteroalkyl. In embodiments. R2is unsubstituted methoxy. In embodiments, R2is unsubstituted ethoxy. In embodiments, R2is unsubstituted propoxy. In embodiments, R2is unsubstituted n-propoxy. In embodiments, R2is unsubstituted isopropoxy. In embodiments, R2is unsubstituted butoxy. In embodiments, R2is unsubstituted C3-C8 cycloalkyl. In embodiments, R2is unsubstituted cyclopropyl. In embodiments, R2is unsubstituted cyclobutyl. In embodiments, R2is unsubstituted cyclopentyl. In embodiments, R2is unsubstituted cyclohexyl. In embodiments, R2is unsubstituted cycloheptyl. In embodiments, R2is unsubstituted cyclooctyl. In embodiments, R2is substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R2is unsubstituted oxetanyl. In embodiments,
[0187] In embodiments, R2is hydrogen, halogen, -CX23, -CHX22, -CH2X2. -OCX23, -OCHX22, -CN, -OR2D, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R2is hydrogen, halogen, -CX23, -CHX22. -CH2X2, -CN, -OR2D, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyd, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R2is hydrogen, -F, -Cl, -CF3, -CHF2, -OCF3, -OCHF2, -CN, unsubstituted methyl, unsubstituted isopropyl, unsubstituted methoxy, unsubstituted cyclopropyl,unsubstituted cyclobutyl, unsubstituted oxetanyl,In embodiments, R2is hydrogen, -F, -Cl, -CF3, -CHF2, -CN, unsubstituted methyl, unsubstituted isopropyl, unsubstituted methoxy, unsubstituted cyclopropyl, unsubstituted cyclobutyl, or unsubstituted oxetanyl. In embodiments. R2is, In embodiments, R2isembodiments, R2isIn embodiments, R2is
[0188] In embodiments, a substituted R3(e.g., substituted alkyl, substituted heteroalky l, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R3is substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R3is substituted, it is substituted with at least one substituent group. In embodiments, when R3is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R3is substituted, it is substituted with at least one lower substituent group.
[0189] In embodiments, R3is hydrogen. In embodiments, R3is halogen. In embodiments, R3is -F. In embodiments. R3is -Cl. In embodiments, R3is -Br. In embodiments, R3is -I. In embodiments, R3is -CCl3. In embodiments, R3is -CB. In embodiments, R3is -CF3. In embodiments, R3is -CI3. In embodiments, R3is -CH2Cl. In embodiments, R3is -CH2Br. In embodiments, R3is -CH2F. In embodiments, R3is -CH2I. In embodiments, R3is -CHCI2. In embodiments, R3is -CHBr2. In embodiments, R3is -CHF2. In embodiments, R3is -CHI2. In embodiments, R3is -CN. In embodiments, R3is -OH. In embodiments, R3is -NH2. In embodiments, R3is -CONH2. In embodiments, R3is -NO2. In embodiments, R3is -SH. In embodiments, R3is -SO3H. In embodiments, R3is -OSO3H. In embodiments, R3is -SO2NH2. In embodiments, R3is -ONH2. In embodiments, R3is -NHC(O)NH2. In embodiments, R3is -NHSO2H. In embodiments, R3is -NHC(O)H. In embodiments, R3is -NHC(O)OH. In embodiments, R3is -OCCI3. In embodiments, R3is -OCBr3. In embodiments, R3is -OCF3. In embodiments, R3is -OCI3. In embodiments, R3is -OCH2Cl.In embodiments, R3is -OCHzBr In embodiments, R1is -OCH2F. In embodiments, R3is -OCH2I. In embodiments. R3is -OCHCl2. In embodiments, R3is -OCHBQ. In embodiments, R3is -OCHF2. In embodiments, R3is -OCHI2. In embodiments, R3is -SF5. In embodiments, R3is -N3. In embodiments, R3is unsubstituted C1-C4 alkyl. In embodiments, R3is unsubstituted methyl. In embodiments, R3is unsubstituted ethyl. In embodiments, R3is unsubstituted propyl. In embodiments, R3is unsubstituted n-propyl. In embodiments, R3is unsubstituted isopropyl. In embodiments, R3is unsubstituted butyl. In embodiments, R3is unsubstituted n-but l. In embodiments, R3is unsubstituted isobutyl. In embodiments, R3is unsubstituted tert-butyl. In embodiments, R3is unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R3is unsubstituted methoxy. In embodiments, R3is unsubstituted ethoxy. In embodiments, R3is unsubstituted propoxy. In embodiments. R3is unsubstituted n-propoxy. In embodiments, R3is unsubstituted isopropoxy. In embodiments, R3is unsubstituted butoxy. In embodiments, R3is unsubstituted C3-C8 cycloalkyl. In embodiments, R' is unsubstituted cyclopropyl. In embodiments, R3is unsubstituted cyclobutyl. In embodiments, R3is unsubstituted cyclopentyl. In embodiments, R3is unsubstituted cyclohexyl. In embodiments, R3is unsubstituted cycloheptyl. In embodiments, R3is unsubstituted cyclooctyd. In embodiments, R3is substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0190] In embodiments, R3is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl. In embodiments, R3is hydrogen or -F.
[0191] In embodiments, a substituted R4(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R4is substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R4is substituted, it is substituted with at least one substituent group. In embodiments, when R4is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R4is substituted, it is substituted with at least one lower substituent group.
[0192] In embodiments, R4is hydrogen. In embodiments, R4is halogen. In embodiments, R4is -F. In embodiments, R4is -Cl. In embodiments, R4is -Br. In embodiments, R4is -I.In embodiments, R4is -CCI3. In embodiments, R4is -CBn. In embodiments, R4is -CF3. In embodiments, R4is -CI3. In embodiments, R4is -CH2Cl, In embodiments. R4is -Ct Br. In embodiments, R4is -CH2F. In embodiments, R4is -CH2I. In embodiments, R4is -CHCh. In embodiments, R4is -CHBi2. In embodiments, R4is -CHF2. In embodiments, R4is -CHI2. In embodiments, R4is -CN. In embodiments, R4is -OH. In embodiments, R4is -NH2. In embodiments, R4is -CONH2. In embodiments, R4is -NO2. In embodiments, R4is -SH. In embodiments, R4is -SO3H. In embodiments, R4is -OSO3H. In embodiments, R4is -SO2NH2. In embodiments, R4is -ONH2. In embodiments, R4is -NHC(O)NH2. In embodiments, R4is -NHSO2H. In embodiments, R4is -NHC(O)H. In embodiments, R4is -NHC(O)OH. In embodiments, R4is -OCCI3. In embodiments, R4is -OCBn. In embodiments, R4is -OCF3. In embodiments, R4is -OCI3. In embodiments, R4is -OCH2CI. In embodiments, R4is -OCH2Br. In embodiments, R4is -OCH2F. In embodiments, R4is -OCH2I. In embodiments, R4is -OCHCk. In embodiments, R4is -OCHBft. In embodiments, R4is -OCHF2. In embodiments, R4is -OCHI2. In embodiments, R4is -SF5. In embodiments, R4is -N3. In embodiments, R4is unsubstituted C1-C4 alkyl. In embodiments, R4is unsubstituted methyl. In embodiments, R4is unsubstituted ethyl. In embodiments, R4is unsubstituted propyl. In embodiments, R4is unsubstituted n-propyl. In embodiments, R4is unsubstituted isopropyl. In embodiments, R4is unsubstituted butyl. In embodiments, R4is unsubstituted n-butyl. In embodiments, R4is unsubstituted isobutyl. In embodiments, R4is unsubstituted tert-butyl. In embodiments, R4is unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R4is unsubstituted methoxy. In embodiments, R4is unsubstituted ethoxy. In embodiments, R4is unsubstituted propoxy. In embodiments, R4is unsubstituted n-propoxy. In embodiments, R4is unsubstituted isopropoxy. In embodiments, R4is unsubstituted butoxy. In embodiments, R4is unsubstituted C3-C8 cycloalkyl. In embodiments, R4is unsubstituted cyclopropyl. In embodiments, R4is unsubstituted cyclobutyl. In embodiments, R4is unsubstituted cyclopentyl. In embodiments, R4is unsubstituted cyclohexyl. In embodiments, R4is unsubstituted cycloheptyl. In embodiments, R4is unsubstituted cyclooctyl. In embodiments, R4is substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0193] In embodiments, R4is hydrogen, halogen, unsubstituted C1-C4 alkyd, or unsubstituted C3-C8 cycloalkyl. In embodiments, R4is hydrogen, -F, or -CL
[0194] In embodiments, a substituted R5(e.g.. substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R5is substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R5is substituted, it is substituted with at least one substituent group. In embodiments, when R5is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R5is substituted, it is substituted with at least one lower substituent group.
[0195] In embodiments, R5is hydrogen. In embodiments, R5is halogen. In embodiments, R5is -F. In embodiments, R5is -Cl. In embodiments, R5is -Br. In embodiments, R5is -I. In embodiments, R5is -CCI3. In embodiments, R5is -CBrs. In embodiments, R5is -CF3. In embodiments, R5is -CI3. In embodiments, R5is -CH2Cl, In embodiments, R5is -CFFBr. In embodiments, R5is -CH2F. In embodiments, R5is -CH2I. In embodiments, R5is -CHCh. In embodiments, R5is -CHBr2. In embodiments, R5is -CHF2. In embodiments, R5is -CHI2. In embodiments, R5is -CN. In embodiments, R5is -OH. In embodiments, R5is -NH2. In embodiments, R5is -CONH2. In embodiments, R5is -NO2. In embodiments, R5is -SH. In embodiments, R5is -SO3H. In embodiments, R5is -OSO3H. In embodiments, R5is -SO2NH2. In embodiments. R5is -ONH2. In embodiments, R5is -NHC(O)NH2. In embodiments, R5is -NHSO2H. In embodiments, R5is -NHC(O)H. In embodiments, R5is -NHC(O)OH. In embodiments, R5is -OCCI3. In embodiments, R5is -OCBn. In embodiments, R5is -OCF3. In embodiments, R5is -OCI3. In embodiments, R5is -OCH2CI. In embodiments. R5is -OCH2Br. In embodiments, R5is -OCH2F. In embodiments, R5is -OCH2I. In embodiments, R5is -OCHCI2. In embodiments, R5is -OCHBn In embodiments, R5is -OCHF2. In embodiments, R5is -OCHI2. In embodiments, R5is -SF5. In embodiments, R5is -N3. In embodiments, R5is unsubstituted C1-C4 alkyl. In embodiments, R5is unsubstituted methyl. In embodiments. R5is unsubstituted ethyl. In embodiments, R5is unsubstituted propyl. In embodiments, R5is unsubstituted n-propyl. In embodiments, R5is unsubstituted isopropyl. In embodiments, R5is unsubstituted butyl. In embodiments, R5is unsubstituted n-butyl. In embodiments, R5is unsubstituted isobutyl. In embodiments, R5is unsubstituted tert-butyl. In embodiments, R5is unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R5is unsubstituted methoxy. In embodiments, R5isunsubstituted ethoxy. In embodiments, R5is unsubstituted propoxy. In embodiments, R5is unsubstituted n-propoxy. In embodiments, R5is unsubstituted isopropoxy. In embodiments, R5is unsubstituted butoxy. In embodiments, R5is unsubstituted C3-C8 cycloalkyl. In embodiments, R5is unsubstituted cyclopropyl. In embodiments, R5is unsubstituted cyclobutyl. In embodiments, R5is unsubstituted cyclopentyl. In embodiments, R5is unsubstituted cyclohexyl. In embodiments, R5is unsubstituted cycloheptyl. In embodiments, R5is unsubstituted cyclooctyd. In embodiments, R5is substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0196] In embodiments, R5is hydrogen, halogen, unsubstituted C1-C4 alkyd, or unsubstituted C3-C8 cycloalkyl. In embodiments, R5is hydrogen, -F, -Cl, or unsubstituted cyclopropyl. In embodiments. R5is hydrogen, -F, -Cl, -I, or unsubstituted cyclopropyl.
[0197] In embodiments, a substituted R6(e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyd, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R6is substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R6is substituted, it is substituted with at least one substituent group. In embodiments, when R6is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R6is substituted, it is substituted with at least one lower substituent group.
[0198] In embodiments, R6is hydrogen. In embodiments, R6is halogen. In embodiments, R6is -F. In embodiments, R6is -Cl. In embodiments, R6is -Br. In embodiments, R6is -I. In embodiments, R6is -CCh. In embodiments, R6is -CBr? In embodiments, R6is -CF3. In embodiments, R6is -CI3. In embodiments, R6is -CH2Cl, In embodiments. R6is -CFFBr. In embodiments, R6is -CH2F. In embodiments, R6is -CH2I. In embodiments, R6is -CHCh. In embodiments, R6is -CHBr2. In embodiments, R6is -CHF2. In embodiments, R6is -CHI2. In embodiments, R6is -CN. In embodiments, R6is -OH. In embodiments, R6is -NH2. In embodiments, R6is -CONH2. In embodiments, R6is -NO2. In embodiments, R6is -SH. In embodiments, R6is -SO3H. In embodiments, R6is -OSO3H. In embodiments, R6is -SO2NH2. In embodiments, R6is -ONH2. In embodiments, R6is -NHC(O)NH2. In embodiments, R6is -NHSO2H. In embodiments, R6is -NHC(O)H. In embodiments, R6is -NHC(O)OH. In embodiments, R6is -OCCh. In embodiments, R6is -OCBn. In embodiments, R6is -OCF3. In embodiments, R6is -OCI3. In embodiments, R6is -OCH2Cl, In embodiments, R6is -OCFBBr. In embodiments, R6is -OCH2F. In embodiments, R6is -OCH2I. In embodiments, R6is -OCHCk. In embodiments, R6is -OCHB^. In embodiments, R6is -OCHF2. In embodiments, R6is -OCHI2. In embodiments, R6is -SF5. In embodiments, R6is -N3. In embodiments, R6is substituted or unsubstituted Ci-Ce alkyl. In embodiments, R6is substituted or unsubstituted C1-C4 alkyl. In embodiments, R6is unsubstituted C1-C4 alkyl. In embodiments, R6is unsubstituted methyl. In embodiments, R6is unsubstituted ethyl. In embodiments, R6is unsubstituted propyl. In embodiments, R6is unsubstituted n-propyl. In embodiments, R6is unsubstituted isopropyl. In embodiments, R6is unsubstituted butyl. In embodiments. R6is unsubstituted n-butyl. In embodiments, R6is unsubstituted isobutyl. In embodiments, R6is unsubstituted tert-butyl. In embodiments, R6is unsubstituted pentyl. In embodiments, R6is unsubstituted unsubstituted n-pent l. In embodiments, R6is unsubstituted hexyl. In embodiments, R6is unsubstituted n-hexyl. In embodiments, R6is unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R6is unsubstituted methoxy. In embodiments, R6is unsubstituted ethoxy. In embodiments, R6is unsubstituted propoxy. In embodiments, R6is unsubstituted n-propoxy. In embodiments, R6is unsubstituted isopropoxy. In embodiments, R6is unsubstituted butoxy. In embodiments, R6is substituted or unsubstituted C3-C8 cycloalkyl. In embodiments, R6is unsubstituted C3-Cs cycloalkyl. In embodiments. R6is unsubstituted cyclopropyl. In embodiments. R6is unsubstituted cyclobutyl. In embodiments, R6is unsubstituted cyclopentyl. In embodiments, R6is unsubstituted cyclohexyl. In embodiments, R6is unsubstituted cycloheptyl. In embodiments, R6is unsubstituted cyclooctyl. In embodiments, R6is substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R6is substituted or unsubstituted bridged cycloalkyl. In embodiments, R6is substituted or unsubstituted bridged heterocycloalkyl. In embodiments, R6is substituted or unsubstituted spirocyclic cycloalkyl. In embodiments, R6is substituted or unsubstituted spirocyclic heterocycloalkyl. In embodiments, R6is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted C3-C8 cycloalkyl). In embodiments, R6is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted 3 to 8 membered heterocycloalkyl). In embodiments, R6is -(unsubstituted Ci-C4 alkyl ene)-(substituted or unsubstituted phenyl). In embodiments, R6is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted 5 to 10 membered heteroaryl). In embodiments, R6is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted 5 to 6membered heteroaryl). In embodiments, R6is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted pyridyl). In embodiments, R6is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted pyrimidyl).
[0199] In embodiments, R6is substituted or unsubstituted Ci-Ce alkyl, substituted or unsubstituted C'3-C's cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R6is substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C?-Cs cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R6is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted n-butyl, unsubstituted n-pentyl, unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl,ethyl, unsubstituted isopropyl, unsubstituted cyclopropyl, unsubstituted cyclobutyl,unsubstituted cyclopentyl, unsubstituted cyclohexyl,. In embodiments, R6is CH3CH3CH3X^CH3X^CH3. In embodiments, R6is. In embodiments, R6isIn embodiments, R6is CH3 inembodiments.embodiments, R6is CH3 in embodiments, R6is CH3 in embodiments,embodiments.embodiments, R6isodiments, R6isIn embodiments, R6isCH3. In embodiments, R6is. In embodiments, R6is.,.,In embodiments, R6is. In embodiments, R6is. In embodiments, R6is.,.,. Inembodiments, R6is. In embodiments, R6is. In embodiments, R66IS. In embodiments, R isIn embodiments, R6is. Inembodiments, R6is. In embodiments,embodiments, R6is,. In embodiments, R6is. Inembodiments, R6is. In embodiments, R6is. In embodiments, R6is. In embodiments, R6is. In embodiments, R6is. In CH3embodiments, R6is. In embodiments, R6is. In embodiments, R6isF.,. In embodiments, R6is. Inembodiments, R6is. In embodiments, R6is. In embodiments, R6is.,. In embodiments, R6is. In CHF2embodiments, R6is. In embodiments, R6is. In embodiments. R6is
[0200] In embodiments, a substituted R7(e.g.. substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and / or substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R7is substituted with a plurality of groups selected from substituent groups, sizelimited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when R7is substituted, it is substituted with at least one substituent group. In embodiments, when R7is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R7is substituted, it is substituted with at least one lower substituent group.
[0201] In embodiments, R7is hydrogen. In embodiments, R7is halogen. In embodiments, R7is -F. In embodiments, R7is -Cl. In embodiments, R7is -Br. In embodiments, R7is -I. In embodiments, R7is -CCI3. In embodiments, R7is -CBrs. In embodiments, R7is -CF3. In embodiments, R7is -CI3. In embodiments, R7is -CH2Cl, In embodiments, R7is -CFFBr. In embodiments, R7is -CH2F. In embodiments, R7is -CH2I. In embodiments, R7is -CHCh. In embodiments, R7is -CHBr2. In embodiments, R7is -CHF2. In embodiments, R7is -CHI2. In embodiments, R7is -CN. In embodiments, R7is -OH. In embodiments, R7is -NH2. In embodiments, R7is -CONH2. In embodiments, R7is -NO2. In embodiments, R7is -SH. In embodiments, R7is -SO3H. In embodiments, R7is -OSO3H. In embodiments, R7is -SO2NH2. In embodiments. R7is -ONH2. In embodiments, R7is -NHC(O)NH2. In embodiments, R7is -NHSO2H. In embodiments, R7is -NHC(O)H. In embodiments, R7is -NHC(O)OH. In embodiments, R7is -OCCI3. In embodiments, R7is -OCBn. In embodiments, R7is -OCF3. In embodiments, R7is -OCI3. In embodiments, R7is -OCH2CI. In embodiments. R7is -OCH2Br. In embodiments, R7is -OCH2F. In embodiments, R7is -OCH2I. In embodiments, R7is -OCHCI2. In embodiments, R7is -OCHBn In embodiments, R7is -OCHF2. In embodiments, R7is -OCHI2. In embodiments, R7is -SF5. In embodiments, R7is -N3. In embodiments, R7is substituted or unsubstituted C1-C4 alkyl. In embodiments, R7is unsubstituted C1-C4 alkyl. In embodiments, R7is unsubstituted methyl. In embodiments, R7is unsubstituted ethyl. In embodiments, R7is unsubstituted propyl. In embodiments, R7is unsubstituted n-propyl. In embodiments, R7is unsubstituted isopropyl. In embodiments, R7is unsubstituted buty l. In embodiments, R7is unsubstituted n-butyl. In embodiments, R7is unsubstituted isobutyl. In embodiments, R7is unsubstituted tert-butyl. In embodiments, R7is unsubstituted 2 to 6 membered heteroalkyl. Inembodiments, R7is unsubstituted methoxy. In embodiments, R7is unsubstituted ethoxy. In embodiments, R7is unsubstituted propoxy. In embodiments, R7is unsubstituted n-propoxy. In embodiments, R7is unsubstituted isopropoxy. In embodiments, R7is unsubstituted butoxy. In embodiments, R7is substituted or unsubstituted C3-C8 cycloalkyl. In embodiments, R7is unsubstituted C3-C8 cycloalkyl. In embodiments, R7is unsubstituted cyclopropyl. In embodiments. R7is unsubstituted cyclobutyl. In embodiments, R7is unsubstituted cyclopentyl. In embodiments. R7is unsubstituted cyclohexyl. In embodiments, R7is unsubstituted cycloheptyl. In embodiments, R7is unsubstituted cyclooctyl. In embodiments, R7is substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R7is substituted or unsubstituted bridged cycloalky 1. In embodiments, R7is substituted or unsubstituted bridged heterocycloalkyl. In embodiments, R7is substituted or unsubstituted spirocyclic cycloalkyl. In embodiments, R7is substituted or unsubstituted spirocyclic heterocycloalkyl. In embodiments, R7is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted C3-C8 cycloalky l). In embodiments, R7is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted 3 to 8 membered heterocycloalkyl). In embodiments, R7is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted phenyl). In embodiments, R7is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted 5 to 10 membered heteroaryl). In embodiments, R7is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted 5 to 6 membered heteroaryl). In embodiments, R7is -(unsubstituted C1-C4 alkylene)-(substituted or unsubstituted pyridyl). In embodiments, R7is -(unsubstituted Ci-C4 alkylene)-(substituted or unsubstituted pyrimidyl).
[0202] In embodiments, R7is -CD3, unsubstituted methyl, unsubstituted ethyl,substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C?-Cs cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R7is unsubstituted methyl, unsubstituted ethyl, unsubstituted cyclopropyl,,f1 1- r» 7 •. In embodiments, R is -CDs. In embodiments, R7is. In embodiments, R7is. Inembodiments, R7is. In embodiments, R7is. In embodiments, R7isCH3 in embodiments, R7is CH3. In embodiments, R7is CH3In embodiments, R7is CH3. in embodiments, R7isINembodiments, R7is O. In embodiments, R7is O. Inembodiments, R7is O. In embodiments, R7is O. In embodiments.R7is O. In embodiments, R7is o. In embodiments. R7isembodiments, R7is. In embodiments, R7is. In embodiments, R7is. In embodiments, R7isH. In embodiments, R7is CH3 in embodiments, R7is3. In embodiments, R77.is O O in embodiments, R is CH3.bk / 0 0 in embodiments, R7isjnembodiments, R7is. CH3CH3R'OHH3in embodiments, R7is.TIn em.bodiments, T R* 7 i •sOll' CH3H3. in embodiments, R7isIn embodiments, R7is.,. In embodiments, R isO O7In embodiments, R7is 0 0 In embodiments, R CH3Y N3O^ isIn embodiments,. In embodiments, R7is, s7is, In embodiments, R7is,. In embodiments, R7is, embodiments, R7is,. In embodiments, R7is
[0203] In embodiments, a substituted ring formed when R6and R7substituents bonded to the same nitrogen atom are joined (e.g., substituted heterocycloalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted ring formed when R6and R7substituents bonded to the same nitrogen atom are joined is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups: each substituent group, size-limited substituent group, and / or lower substituent group may optionally be different. In embodiments, when the substituted ring formed when R6and R7substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one substituent group. In embodiments, when the substituted ring formed when R6and R7substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when the substituted ring formed when R6and R7substituents bonded to the same nitrogen atom are joined is substituted, it is substituted with at least one lower substituent group.
[0204] In embodiments, R6and R7substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R6and R7substituents are joined to form a substituted or unsubstituted bridged heterocycloalkyl. In embodiments, R6and R7substituents are joined to form a substituted or unsubstituted spirocyclic heterocycloalkyl. In embodiments, R6and R7substituents, together with the nitrogen atom toembodiments, R6and R7substituents, together with the nitrogen atom to which they areR6and R7substituents, together with the nitrogen atom to which they are bonded, are joinedto form CH3jnembodiments, R6and R7substituents, together with the nitrogen atomto which they are bonded, are joined to formembodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formwhich they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. in embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atomto which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atomto which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments. R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to formN3. In embodiments, R6and R, substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to CF3which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formto w hich they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formin embodiments, R6and R' substituents, together with the nitrogenatom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined toformIn embodiments. R6and R7substituents, together with thenitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joinedto formIn embodiments, R6and R7substituents, together with the nitrogenatom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogenatom to which they are bonded, are joined to form. in embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined toform. In embodiments, R6and R7substituents, together with the nitrogenatom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to formsubstituents, together with the nitrogen atom to which they are bonded, are joined to formIn embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to formwhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form. In embodiments, R6and R7substituents, together with the nitrogen atom towhich they are bonded, are joined to form
[0205] In embodiments, when R1is substituted, R1is substituted with one or more first substituent groups denoted by R1 1as explained in the definitions section above in the description of ‘’first substituent group(s)’’. In embodiments, when an R1 1substituent group is substituted, the R1 1substituent group is substituted with one or more second substituent groups denoted by R1 2as explained in the definitions section above in the description of “first substituent group(s)". In embodiments, when an R1 2substituent group is substituted, the R1 2substituent group is substituted with one or more third substituent groups denoted by R1 3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1, R1-1, R1 2, and R1 3have values corresponding to the values of Rww, RWW 1, Rww 2,anc|Rww..^reSpectively, as explained in the definitions section above in the description of “first substituent group(s)’; wherein Rww. R1.RW.2 and RWW 3correspond to R1, R1 1, R1 2, and R1 3, respectively.
[0206] In embodiments, when two R1substituents are optionally j oined to form a moiety that is substituted (e.g., a substituted cycloalkyd, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl), the moiety is substituted with one or more first substituent groups denoted by R1 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1 1substituent group is substituted, the R1 1substituent group is substituted with one or more second substituent groups denoted by R1 2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12substituent group is substituted, the R1 2substituent group is substituted with one or more third substituent groups denoted by R1 3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1, R.1 1. R1 2, and R1 3have values corresponding to the values of Rww, RWW 1, Rww 2, and Rww-3, respectively, as explained in the definitions section above in the description of “first substituent group(s)7’, wherein Rww, RWW 1,RWW.2anc[Rww.3correSpOnc[ to R1, R1-1, R1 2, and R1 3, respectively.
[0207] In embodiments, when R1Ais substituted, R1Ais substituted with one or more first substituent groups denoted by R1A 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1A 1substituent group is substituted, the R1A 1substituent group is substituted with one or more second substituent groups denoted by R1A2as explained in the definitions section above in the description of “first substituent group(s)’'. In embodiments, when an R1A 2substituent group is substituted,the R1A 2substituent group is substituted with one or more third substituent groups denoted by R1A 3as explained in the definitions section above in the description of “first substituent group(s)’’. In the above embodiments, R1A, R1AR1A'2, and R1A3have values corresponding to the values of Rww, RWWJ, Rww-2. and Rww\ respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww, RW1;ww.2, and RWW3correspond to R1 A, RI AI. R1A 2, and R1A3, respectively.
[0208] In embodiments, when R1Bis substituted, R1Bis substituted with one or more first substituent groups denoted by R1B 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1B 1substituent group is substituted, the R1B 1substituent group is substituted with one or more second substituent groups denoted by R1B 2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1B 2substituent group is substituted, the R1B 2substituent group is substituted with one or more third substituent groups denoted by R1B 3as explained in the definitions section above in the description of “first substituent group(s)'’. In the above embodiments, R1B, R1B A, R1B 2, and R1B 3have values corresponding to the values of Rw, Rww-1, Rw-2. and R3, respectively, as explained in the definitions section above in the description of “first substituent group(s)’’, wherein Rww?RwwRWW22Sand RWW 3correspond to R1B, R1B 1, R1B 2, and R1R3, respectively.
[0209] In embodiments, when R1Aand R1Bsubstituents bonded to the same nitrogen atom are optionally joined to form a moiety that is substituted (e.g., a substituted heterocycloalkyl or substituted heteroaryl), the moiety is substituted with one or more first substituent groups denoted by R1A 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1A 1substituent group is substituted, the R1A 1substituent group is substituted with one or more second substituent groups denoted by R1A 2as explained in the definitions section above in the description of “first substituent group(s)’’. In embodiments, when an R1A 2substituent group is substituted, the R1 2substituent group is substituted with one or more third substituent groups denoted by R1A3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1A 1, R1A 2, and R1A 3have values corresponding to the values of Rww\RWW.2ANC|RWW.3reSpectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW 1, RWW 2and RWW 3correspond to R1A-1, R1 2and R1A3, respectively.
[0210] In embodiments, when R1Aand R1Bsubstituents bonded to the same nitrogen atom are optionally joined to form a moiety that is substituted (e.g., a substituted heterocycloalkyl or substituted heteroaryl), the moiety is substituted with one or more first substituent groups denoted by R1B 1as explained in the definitions section above in the description of '‘first substituent group(s)’'. In embodiments, when an R1B 1substituent group is substituted, the R1B 1substituent group is substituted with one or more second substituent groups denoted by R1B 2as explained in the definitions section above in the description of "first substituent group(s)”. In embodiments, when an R1B 2substituent group is substituted, the R1B 2substituent group is substituted with one or more third substituent groups denoted by R1B 3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1B 1. R1B 2, and R1B 3have values corresponding to the values of RWW I. J^WW.2an(j j^ww.3reSpectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RW 1, R*W 2;and RWW 3correspond to RIB ', R1B 2, and R1B 3, respectively.
[0211] In embodiments, when R1Cis substituted, R1Cis substituted with one or more first substituent groups denoted by R1C 1as explained in the definitions section above in the description of “first substituent group(s)’’. In embodiments, when an R1C 1substituent group is substituted, the R1C 1substituent group is substituted with one or more second substituent groups denoted by R1C 2as explained in the definitions section above in the description of “first substituent group(s)". In embodiments, when an R1C 2substituent group is substituted, the R1C 2substituent group is substituted with one or more third substituent groups denoted by R1C 3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1C, R1C 1, R1C 2, and R1C?have values corresponding to the values of Rww,respectively, as explained in the definitions section above in the description of “first substituent group! s)“. wherein RWVv, RwRWW.2, and RWW 3correspond to R1C, R1C 1, R1C 2, and R1C 3, respectively.
[0212] In embodiments, when R1Dis substituted, R1Dis substituted with one or more first substituent groups denoted by R1D 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1D 1substituent group is substituted, the R1D 1substituent group is substituted with one or more second substituent groups denoted by R1D 2as explained in the definitions section above in the description of “first substituent group(s)’'. In embodiments, when an R1D 2substituent group is substituted,the R1E> 2substituent group is substituted with one or more third substituent groups denoted by R1D 3as explained in the definitions section above in the description of “first substituent group(s)’’. In the above embodiments, R1D, R1DR1D 2, and R1D 3have values corresponding to the values of Rww, RWWJ, Rww-2. and Rww\ respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww, RW1;pww.2, and RWW3correspond to R1D, R1D l, R1D 2, and R1D 3, respectively.
[0213] In embodiments, when R2is substituted, R2is substituted with one or more first substituent groups denoted by R2 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2 1substituent group is substituted, the R2 1substituent group is substituted with one or more second substituent groups denoted by R22as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R22substituent group is substituted, the R22substituent group is substituted with one or more third substituent groups denoted by R23as explained in the definitions section above in the description of “first substituent group(s)'’. In the above embodiments, R2. R2 A, R22, and R23have values corresponding to the values of Rww. Rww-1, Rww'2, and Rww'3, respectively, as explained in the definitions section above in the description of “first substituent group(s)’’, wherein Rww?RwwRWW.2 and RWW 3correspond to R2, R2 1, R22, and R23, respectively.
[0214] In embodiments, when R2Ais substituted, R2Ais substituted with one or more first substituent groups denoted by R2A 1as explained in the definitions section above in the description of “first substituent group(s)7’. In embodiments, when an R2A 1substituent group is substituted, the R2A 1substituent group is substituted with one or more second substituent groups denoted by R2A2as explained in the definitions section above in the description of “first substituent group(s)’'. In embodiments, when an R2A 2substituent group is substituted, the R2A 2substituent group is substituted with one or more third substituent groups denoted by R2A3as expiainec[ inthe definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2A, R2AR2A 2, and R2A3have values corresponding to the values of Rww, RWW 1, Rww-2, and Rww-\ respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww. RWW 1, pww.2, and RWW 3correspond to R2A, R2AA, R2A 2, and R2A3, respectively.
[0215] In embodiments, when R2Bis substituted, R2Bis substituted with one or more first substituent groups denoted by R2B 1as explained in the definitions section above in thedescription of “first substituent group(s)”. In embodiments, when an R2B 1substituent group is substituted, the R2B 1substituent group is substituted with one or more second substituent groups denoted by R2B 2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2B 2substituent group is substituted, the R2B 2substituent group is substituted with one or more third substituent groups denoted by R2B 3as explained in the definitions section above in the description of “first substituent group(s)’; In the above embodiments, R2B, R2B 1, R2B 2, and R2B 3have values corresponding to the values of Rww, RwwRww-23 an(| RWW5 reSpecpve]yasexplained in the definitions section above in the description of “first substituent group(s)”, wherein Rww, RWW 1, RWW.2, and RWW3correspond to R2B, R2B 1, R2B 2, and R2B 3. respectively.
[0216] In embodiments, when R2Aand R2Bsubstituents bonded to the same nitrogen atom are optionally joined to form a moiety that is substituted (e.g., a substituted heterocycloalkyl or substituted heteroaryl), the moiety is substituted with one or more first substituent groups denoted by R2A 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2A 1substituent group is substituted, the R2A 1substituent group is substituted with one or more second substituent groups denoted by R2A2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2A 2substituent group is substituted, the R2A 2substituent group is substituted with one or more third substituent groups denoted by R2A3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2A 1, R2A2, and R2A3have values corresponding to the values of RWW 1, RWW.2,ANC[ RW\V.3,reSpectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww-1, RWW 2, and RWW 3correspond to R2A 1, R2A 2, and R2A 3, respectively.
[0217] In embodiments, when R2Aand R2Bsubstituents bonded to the same nitrogen atom are optionally joined to form a moiety that is substituted (e.g., a substituted heterocycloalkyl or substituted heteroaryl), the moiety is substituted with one or more first substituent groups denoted by R2B 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2B 1substituent group is substituted, the R2B 1substituent group is substituted with one or more second substituent groups denoted by R2B 2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2B 2substituent group is substituted, the R2B 2substituent group is substituted with one or more third substituent groups denoted by R2B 3as explained in the definitions section above in the description of "‘first substituent group(s)". In the above embodiments, R2BR2B 2, and R2B 3have values corresponding to the values of RWW 1, ^WW2anc[ RWW.3,reSpectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW 1, RWW 25 anc| RWW.3correspond to R2B 1. R2B 2, and R2Brespectively.
[0218] In embodiments, when R2Cis substituted, R2Cis substituted with one or more first substituent groups denoted by R2C 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2C 1substituent group is substituted, the R2C 1substituent group is substituted with one or more second substituent groups denoted by R2C 2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2C 2substituent group is substituted, the R2C 2substituent group is substituted with one or more third substituent groups denoted by R2C 3as explained in the definitions section above in the description of “first substituent group(s)'’. In the above embodiments, R2C, R2C A, R2C 2, and R2C 3have values corresponding to the values of Rw, Rww-1. Rw-2. and R3, respectively, as explained in the definitions section above in the description of “first substituent group(s)’’, wherein Rww?RwwRWW.2 and RWW 3correspond to R2C, R2C 1, R2C 2, and R2C3, respectively.
[0219] In embodiments, when R2Dis substituted, R2Dis substituted with one or more first substituent groups denoted by R2D 1as explained in the definitions section above in the description of “first substituent group(s)7’. In embodiments, when an R2D 1substituent group is substituted, the R2D 1substituent group is substituted with one or more second substituent groups denoted by R2D 2as explained in the definitions section above in the description of “first substituent group(s)’'. In embodiments, when an R2D 2substituent group is substituted, the R2E> 2substituent group is substituted with one or more third substituent groups denoted by R2E>.3as expiainec[ inthe definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2D, R2D 1, R2D 2, and R2D 3have values corresponding to the values of Rww, Rww-1, Rww-2, and Rww-3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww. RWW 1, RWW.2 and RWW 3correspond to R2D, R2D-1, R2D 2, and R2D 3, respectively.
[0220] In embodiments, when R3is substituted, R3is substituted with one or more first substituent groups denoted by R3 1as explained in the definitions section above in thedescription of “first substituent group(s)”. In embodiments, when an R3 1substituent group is substituted, the R3 1substituent group is substituted with one or more second substituent groups denoted by R3 2as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R32substituent group is substituted, the R3 2substituent group is substituted with one or more third substituent groups denoted by R3 3as explained in the definitions section above in the description of “first substituent group(s)’; In the above embodiments, R3, R3 1, R32, and R33have values corresponding to the values of Rww, RWW 1RWW.2RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww, RWW 1, RWW.2, and RWW3correspond to R3, R3’, R32, and R33, respectively.
[0221] In embodiments, when R4is substituted, R4is substituted with one or more first substituent groups denoted by R4 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4 1substituent group is substituted, the R4 1substituent group is substituted with one or more second substituent groups denoted by R42as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R42substituent group is substituted, the R42substituent group is substituted with one or more third substituent groups denoted by R43as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R4, R4 1. R42, and R43have values corresponding to the values of Rww. Rww 4, Rww'2, and Rww'3, respectively, as explained in the definitions section above in the description of “first substituent group(s)’’, wherein Rww, RwwRW.2 and RWW 3correspond to R4, R4 1, R42, and R43, respectively.
[0222] In embodiments, when R5is substituted, R5is substituted with one or more first substituent groups denoted by R5 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5 1substituent group is substituted, the R5 1substituent group is substituted with one or more second substituent groups denoted by R5 2as explained in the definitions section above in the description of “first substituent group(s)’'. In embodiments, when an R52substituent group is substituted, the R5 2substituent group is substituted with one or more third substituent groups denoted by R5 3as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R5, R5 1, R52, and R53have values corresponding to the values of Rww, RWW I. Rww'2, and Rww'3, respectively, as explained in the definitionssection above in the description of “first substituent group(s)”, wherein Rww, R,, W1)pww.2, and RWW3correspond to R5, R5R52. and R53, respectively.
[0223] In embodiments, when R6is substituted. R6is substituted with one or more first substituent groups denoted by R6 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6 1substituent group is substituted, the R6 1substituent group is substituted with one or more second substituent groups denoted by R62as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R62substituent group is substituted, the R62substituent group is substituted with one or more third substituent groups denoted by R6'1as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R6. R6, R62, and R63have values corresponding to the values of Rww. RwxRWW 2ANC| RWW.3 respectively, as explained in the definitions section above in the description of “first substituent group(s)’’, wherein Rww, RWW 13RWW.2, and RWW 3correspond to R6, R6 1, R62, and R63, respectively.
[0224] In embodiments, when R7is substituted, R7is substituted with one or more first substituent groups denoted by R7 1as explained in the definitions section above in the description of “first substituent group(s)7’. In embodiments, when an R7 1substituent group is substituted, the R7 1substituent group is substituted with one or more second substituent groups denoted by R72as explained in the definitions section above in the description of “first substituent group(s)’'. In embodiments, when an R72substituent group is substituted, the R72substituent group is substituted with one or more third substituent groups denoted by R73as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R7, R71, R72, and R73have values corresponding to the values of Rww, Rww-1, Rww-2, and Rww- respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein Rww. RWW i,RWW.2 and RWW 3correspond to R7, R7 1, R72, and R73, respectively.
[0225] In embodiments, when R6and R7substituents are optionally joined to form a moiety that is substituted (e.g., a substituted heterocycloalkyl), the moiety is substituted with one or more first substituent groups denoted by R6 1as explained in the definitions section above in the description of “first substituent group(s)". In embodiments, when an R6 1substituent group is substituted, the R6 1substituent group is substituted with one or more second substituent groups denoted by R62as explained in the definitions section above in thedescription of “first substituent group(s)”. In embodiments, when an R62substituent group is substituted, the R62substituent group is substituted with one or more third substituent groups denoted by R63as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R6 1, R62, and R63have values corresponding to the values of RwwRww-2, and RWW 3,reSpectiVely, as explained in the definitions section above in the description of “first substituent group(s)". wherein Rww-1, RWW 2, and RWW3correspond to R6 1, R62, and R63, respectively.
[0226] In embodiments, when R6and R7substituents are optionally joined to form a moiety that is substituted (e.g., a substituted heterocycloalkyl), the moiety is substituted with one or more first substituent groups denoted by R7 1as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R71substituent group is substituted, the R7 1substituent group is substituted with one or more second substituent groups denoted by R72as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R72substituent group is substituted, the R72substituent group is substituted with one or more third substituent groups denoted by R73as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R7 1, R72, and R73have values corresponding to the values of RWW 1, Rww'2, and RWW 3, respectively, as explained in the definitions section above in the description of “first substituent group(s)’', wherein RWW 1, Rww 2, and RWW 3correspond to R7 1, R72, and R73, respectively.
[0227] In embodiments, the compoundembodiments,the compoundembodiments, the compound is, pIn embodiments, the compound is.,, p, p, p, p, p, p, p, p, p, p,., p, p, pound is, p, s,,, p, pIn embodiments, the compound is, p, p., p,In embodiments, the compound is,In embodiments, the compound is, p s, p, p,., p,, p sIn embodiments, the compound is, p, p,In embodiments, the compound is, p., p, p, pIn embodiments, the compound is, p, p,In embodiments, the compound is. In embodiments, the compound is, p, p s,, p, p, p,, s, p., s, p is, p, p s, ps, p, p,, pIn embodiments, the compound is, p, p, p, p, s,, p, p, p, p u s, p., p is, p, p, p, p,In embodiments, the compound is,, p, p.,, p, p, p, p sIn embodiments, the compound is, p,, p, p, p, s, p s, p, p sIn embodiments, the compound is,,embodiments, the compound is, p,,In embodiments, the compound is, p,, p, p, p, p, p s, p, p., p,., p is, poun s, p, p,, p, p, p. In embodiments, the compound isembodiments, the compound is
[0228] In embodiments, the compound is useful as a comparator compound. In embodiments, the comparator compound can be used to assess the activity of a test compound as set forth in an assay described herein (e.g., in the examples section, or tables).
[0229] In embodiments, the compound is a compound as described herein, including in embodiments. In embodiments the compound is a compound described herein (e.g., in the examples section or claims).III. Pharmaceutical compositions
[0230] In an aspect is provided a pharmaceutical composition including a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0231] In embodiments, the compound is a compound of formula (I), (IA), (II), (III), (IV), (V), (VI), (VII), or (VIII), including all embodiments thereof. In embodiments, the compound is a compound of formula (I), (II), (III), (IV), (V), (VI), (VII), or (VIII), including all embodiments thereof. In embodiments, the compound is a compound of formula (I). In embodiments, the compound is a compound of formula (IA). In embodiments, the compound is a compound of formula (II). In embodiments, the compound is a compound of formula(III). In embodiments, the compound is a compound of formula (IV). In embodiments, the compound is a compound of formula (V). In embodiments, the compound is a compound of formula (VI). In embodiments, the compound is a compound of formula (VII). In embodiments, the compound is a compound of formula (VIII).
[0232] In embodiments, the pharmaceutical composition includes an effective amount of the compound. In embodiments, the pharmaceutical composition includes a therapeutically effective amount of the compound.IV. Methods of use
[0233] In an aspect is provided a method of treating a SARM1-associated disease in a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt of solvate thereof.
[0234] In embodiments, the compound is a compound of formula (I). (IA). (II), (III). (IV). (V), (VI), (VII), or (VIII), including all embodiments thereof. In embodiments, the compound is a compound of formula (I), (II), (III), (IV), (V), (VI), (VII), or (VIII), including all embodiments thereof. In embodiments, the compound is a compound of formula (I). In embodiments, the compound is a compound of formula (IA). In embodiments, the compound is a compound of formula (II). In embodiments, the compound is a compound of formula (III). In embodiments, the compound is a compound of formula (IV). In embodiments, the compound is a compound of formula (V). In embodiments, the compound is a compound of formula (VI). In embodiments, the compound is a compound of formula (VII). In embodiments, the compound is a compound of formula (VIII).
[0235] In embodiments, the SARM1-associated disease is a neurodegenerative disease. In embodiments, the neurodegenerative disease is Alzheimer’s disease. In embodiments, the neurodegenerative disease is Huntington’s disease. In embodiments, the neurodegenerative disease is Parkinson’s disease. In embodiments, the neurodegenerative disease is amyotrophic lateral sclerosis. In embodiments, the neurodegenerative disease is epilepsy. In embodiments, the neurodegenerative disease is chronic traumatic encephalopathy.
[0236] In embodiments, the SARM1 -associated disease is an inflammatory disease. In embodiments, the inflammatory disease is multiple sclerosis. In embodiments, theinflammatory' disease is systemic lupus ery thematosus. In embodiments, the inflammatory disease is rheumatoid arthritis. In embodiments, the inflammatory disease is psoriasis.
[0237] In embodiments, the SARM1-associated disease is a cancer. In embodiments, the cancer is brain cancer. In embodiments, the cancer is glioblastoma. In embodiments, the cancer is a solid tumor (e.g., of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (e g., lymphoma), ovary', pancreas or other endocrine organ (e g., thyroid), prostate, skin (e.g., melanoma or basal cell cancer)) or hematological tumors (e.g., leukemia) at any stage of the disease with or without metastases. In embodiments, the cancer is acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, aty pical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (e.g., osteosarcoma or malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular cancer, Hodgkin lymphoma, hypophary ngeal cancer, intraocular melanoma, islet cell tumors (e.g., endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lymphoma, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary' tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, rhabdomyosarcoma, salivary' gland cancer, sarcoma, Sezary' syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (e.g., gastric) cancer, supratentorial primitive neuroectodermal tumors, T-cell lymphoma,testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, or Wilms’ tumor.
[0238] In embodiments, the SARM1 -associated disease is chemotherapy -induced peripheral neuropathy. In embodiments, the SARM1 -associated disease is diabetic neuropathy. In embodiments, the SARMl-associated disease is Charcot-Marie-Tooth disease. In embodiments, the Charcot-Mari e-Tooth disease is CMT2. In embodiments, the Charcot-Marie-Tooth disease is CMT1. In embodiments, the SARM1 -associated disease is stroke. In embodiments, the SARM1 -associated disease is chronic inflammatory demyelinating polyneuropathy. In embodiments, the SARMl-associated disease is Guillain-Barre syndrome. In embodiments, the SARMl-associated disease is hereditary’ neuropathy with liability to pressure palsy. In embodiments, the SARMl-associated disease is nerve entrapment. In embodiments, the SARMl-associated disease is nerve crust due to trauma. In embodiments, the SARMl-associated disease is alcoholic neuropathy. In embodiments, the SARMl-associated disease is motor endplate myopathy. In embodiments, the SARMl-associated disease is a muscle-wasting disease. In embodiments, the SARMl-associated disease is an eye disease. In embodiments, the SARMl-associated disease is glaucoma. In embodiments, the SARMl-associated disease is autosomal dominant optic atrophy (ADOA). In embodiments, the SARMl-associated disease is a mitochondrial disease. In embodiments, the SARMl-associated disease is traumatic brain injury. In embodiments, the SARMl-associated disease is a neurotrophic viral infection. In embodiments, the SARMl-associated disease is a bone disease. In embodiments, the SARMl-associated disease is a demyelinating disease.
[0239] In an aspect is provided a method of treating a neurodegenerative disease in a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt of solvate thereof. In embodiments, the neurodegenerative disease is as described herein, including in embodiments.
[0240] In an aspect is provided a method of treating an inflammatory disease in a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceuticallyacceptable salt of solvate thereof. In embodiments, the inflammatory disease is as described herein, including in embodiments.
[0241] In an aspect is provided a method of treating cancer in a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt of solvate thereof. In embodiments, the cancer is as described herein, including in embodiments.
[0242] In an aspect is provided a method of modulating SARM1 activity in a subject, the method including administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof.V. Embodiments
[0243] Embodiment Pl. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the formula:Ring A is a heteroaryl;R1is independently halogen, -CX13, -CHX12, -CH2X1, -OCX13, -OCH2X1,-OCHX12, -CN, -SOn1R1D, -SOv1NR1AR1B, -NR1CC(O)NR1AR1B, -N(O)m1, -NR1AR1B, -C(O)NR1AR1B, -OR1D, -SR1D. -NR1ASO2R1D, -NR1AC(O)R1C, -NR1AC(O)OR1C, -SF5, -N3. substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted ary l, or substituted or unsubstituted heteroaryl; two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;zl is an integer from 0 to 6;R2is hydrogen, halogen, -CX23, -CHX22, -CH2X2, -OCX23, -OCH2X2, -OCHX22,-CN, -SOn2R2D, -SOV2NR2AR2B, -NR2CC(O)NR2AR2B, -N(O)m2, -NR2AR2B, -C(O)NR2AR2B,-OR2D, -SR2D, -NR2ASO2R2D, -NR2AC(O)R2C, -NR2AC(O)OR2C, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;R3, R4, and R5are independently hydrogen, halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCI2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCl2, -OCHBr2, -OCHI2, -OCHF2, -OCH2CI, -OCH2Br, -OCH2I. -OCH2F, -CN, -SO3H, -OSO3H. -SO2NH2, -NHNH2. -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NO2. -NH2, -C(O)H, -C(O)OH, -CONH2, -OH, -SH, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;R6and R7are independently hydrogen, -CCl3, -CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F. -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHCl2, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; R6and R7substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl;R1A, R1B, R1C, R1D, R2A, R2B, R2C, and R2Dare independently hydrogen, -CCl3,-CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHCl2, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; R1Aand R1Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2Aand R2Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; each X1and X2is independently -F, -Cl, -Br, or -I;nl and n2 are independently an integer from 0 to 4; andml, m2, vl, and v2 are independently 1 or 2.
[0244] Embodiment P2. The compound of embodiment Pl, wherein Ring A is a 5 to 10 membered heteroaryl.
[0245] Embodiment P3. The compound of embodiment P l, wherein Ring A is pyrazolyl, triazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyridyl, pyridonyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, indazolyl, pyrazolopyridinyl, pyrrolotriazinyl, triazolopyridinyl, imidazopyrazinyl, pyrazolopyrazinyl, or purinyl.
[0246] Embodiment P4. The compound of embodiment Pl, wherein
[0247] Embodiment P5. The compound of any one of embodiments Pl to P4, wherein R1is independently halogen. -CN. or unsubstituted C1-C4 alkyl.
[0248] Embodiment P6. The compound of any one of embodiments Pl to P4, wherein R1is independently -F, -Cl, -CN, or unsubstituted methyl.
[0249] Embodiment P7. The compound of any one of embodiments Pl to P6, wherein zl is 1.
[0250] Embodiment P8. The compound of any one of embodiments Pl to P4, wherein zl is 0.
[0251] Embodiment P9. The compound of embodiment Pl, wherein
[0252] Embodiment PIO. The compound of any one of embodiments Pl to P9, wherein R2is hydrogen, halogen, -CX2s, -CHX22, -CH2X2, -CN, -OR2D, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0253] Embodiment Pl 1. The compound of any one of embodiments Pl to P9, wherein R2is hydrogen, -F, -Cl, -CF3, -CHF2, -CN, unsubstituted methyl, unsubstituted isopropyl, unsubstituted methoxy, unsubstituted cyclopropyl, unsubstituted cyclobutyl, or unsubstituted oxetanyl.
[0254] Embodiment P12. The compound of any one of embodiments Pl to Pl 1, wherein R3is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0255] Embodiment Pl 3. The compound of any one of embodiments Pl to Pl 1, wherein R3is hydrogen or -F.
[0256] Embodiment P14. The compound of any one of embodiments Pl to P13, wherein R4is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0257] Embodiment P15. The compound of any one of embodiments Pl to P13, wherein R4is hydrogen, -F, or -Cl.
[0258] Embodiment Pl 6. The compound of any one of embodiments Pl to P15, wherein R5is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0259] Embodiment Pl 7. The compound of any one of embodiments Pl to Pl 5, wherein R5is hydrogen, -F, -Cl, or unsubstituted cyclopropyl.
[0260] Embodiment Pl 8. The compound of any one of embodiments Pl to Pl 7, wherein R6is substituted or unsubstituted C1-C4 alky l, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0261] Embodiment Pl 9. The compound of any one of embodiments Pl to Pl 7, wherein R6is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl,
[0262] Embodiment P20. The compound of any one of embodiments Pl to Pl 9, wherein R7is substituted or unsubstituted C1-C4 alky l, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0263] Embodiment P21. The compound of any one of embodiments Pl to Pl 9, wherein R7is unsubstituted methyl, unsubstituted ethyl, unsubstituted cyclopropyl,,
[0264] Embodiment P22. The compound of any one of embodiments Pl to P17, wherein R6and R7substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0265] Embodiment P23. The compound of any one of embodiments Pl to P 17, wherein R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form:
[0266] Embodiment P24. A pharmaceutical composition comprising the compound of any one of embodiments Pl to P23, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0267] Embodiment P25. A method of treating a SARM1 -associated disease in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments Pl to P23, or a pharmaceutically acceptable salt or solvate thereof.
[0268] Embodiment P26. The method of embodiment P25, wherein the SARM1-associated disease is a neurodegenerative disease.
[0269] Embodiment P27. The method of embodiment P26, wherein the neurodegenerative disease is Alzheimer's disease. Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, or chronic traumatic encephalopathy.
[0270] Embodiment P28. The method of embodiment P25, wherein the S ARM 1-associated disease is an inflammatory disease.
[0271] Embodiment P29. The method of embodiment P28, wherein the inflammatory disease is multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, or psoriasis.
[0272] Embodiment P30. The method of embodiment P25, wherein the SARM1-associated disease is chemotherapy-induced peripheral neuropathy, diabetic neuropathy, Charcot-Marie-Tooth disease, stroke, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, hereditary neuropathy with liability to pressure palsy, nerve entrapment, nerve crust due to trauma, alcoholic neuropathy, motor endplate myopathy, a muscle-wasting disease, glaucoma, a mitochondrial disease, traumatic brain injury, a neurotrophic viral infection, or a bone disease.
[0273] Embodiment P31. The method of embodiment P30, wherein the Charcot-Marie-Tooth disease is CMT2 or CMT1.
[0274] Embodiment P32. The method of embodiment P25, wherein the SARM1-associated disease is a cancer.
[0275] Embodiment P33. A method of modulating SARM1 activity in a subject, said method comprising administering to the subject the compound of any one of embodiments Pl to P23, or a pharmaceutically acceptable salt or solvate thereof.VI. Additional embodiments
[0276] Embodiment 1. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the formula:whereinRing A is a heteroaryl;R1is independently halogen, -CX13, -CHX12, -CH2X1, -OCX^, -OCH2X1,-OCHX’z, -CN, -SOn1R1D, -SOv1NR1AR1B, -NR1CC(O)NR1AR1B, -N(O)m1, -NR1AR1B, -C(O)NR1AR1B, -OR1D, -SR1D. -NR1ASO2R1D, -NR1AC(O)R1C, -NR1AC(O)OR1C, -SF5, -N3. substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted ary l, or substituted or unsubstituted heteroaiy 1; two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;zl is an integer from 0 to 6;R2is hydrogen, halogen, -CX23, -CHX22, -CH2X2, -OCX23, -OCH2X2, -OCHX22,-CN, -SOn2R2D, -SOv2NR2AR2B, -NR2CC(O)NR2AR2B, -N(O)m2, -NR2AR2B, -C(O)NR2AR2B, -OR2D, -SR2D, -NR2ASO2R2D, -NR2AC(O)R2C, -NR2AC(O)OR2C, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl:R3, R4, and R5are independently hydrogen, halogen, -CC13, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHC12, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NO2. -NH2, -C(O)H, -C(O)OH, -CONH2, -OH, -SH, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;R6and R7are independently hydrogen, -CC13, -CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F. -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHC12, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; R6and R7substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl;R1A, R1B, R1C, R1D, R2A, R2B, R2C, and R2Dare independently hydrogen, -CC13,-CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHC12, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; R1Aand R1Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2Aand R2Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;each X1and X2is independently -F, -Cl, -Br, or -I;nl and n2 are independently an integer from 0 to 4; andml, m2, vl, and v2 are independently 1 or 2.
[0277] Embodiment 2. The compound of embodiment 1. having the formula:
[0279] Embodiment 4. The compound of any one of embodiments 1 to 3, wherein Ring A is a 5 to 10 membered heteroaryl.
[0280] Embodiment 5. The compound of any one of embodiments 1 to 3, wherein Ring A is a 5 membered heteroaryl.
[0281] Embodiment 6. The compound of any one of embodiments 1 to 3, wherein Ring A is pyrazolyl, triazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyridyl, pyrazinyl. pyrimidinyl, pyridazinyl, triazinyl, indazolyl, pyrazolopyridinyl, pyrrolotriazinyl, triazolopyridinyl, imidazopyrazinyl, pyrazolopyrazinyl, or purinyl.
[0282] Embodiment 7. The compound of any one of embodiments 1 to 3, wherein
[0283] Embodiment 8. The compound of any one of embodiments 1 to 7, wherein R1is independently halogen, -CHX12, -CN. -C(O)NR1AR1B, -OR1D, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0284] Embodiment 9. The compound of any one of embodiments 1 to 7, wherein R1is independently -F, -Cl, -CHF2, -CN, -C(O)NH2, -OH, unsubstituted methyl, or unsubstituted cyclopropyl.
[0285] Embodiment 10. The compound of any one of embodiments 1 to 7, wherein two R1substituents may optionally be joined to form a substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
[0286] Embodiment 11. The compound of any one of embodiments 1 to 9, wherein zl is 1 or 2.
[0287] Embodiment 12. The compound of any one of embodiments 1 to 7, wherein zl is
[0288] Embodiment 13. The compound of any one of embodiments 1 to 3, wherein
[0289] Embodiment 14. The compound of any one of embodiments 1 to 13, wherein R2is hydrogen, halogen, -CX23, -CHX22, -CH2X2, -OCX23, -OCHX22, -CN, -OR2D, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0290] Embodiment 15. The compound of any one of embodiments 1 to 13, wherein R2is hydrogen, -F, -Cl, -CFs, -CHF2, -OCF3, -OCHF2, -CN, unsubstituted methyl, unsubstituted isopropyl, unsubstituted methoxy, unsubstituted cyclopropyl, unsubstituted cyclobutyl,
[0291] Embodiment 16. The compound of any one of embodiments 1 to 15, wherein R3is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0292] Embodiment 17. The compound of any one of embodiments 1 to 15, wherein R3is hydrogen or -F.
[0293] Embodiment 18. The compound of any one of embodiments 1 to 17, wherein R4is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0294] Embodiment 19. The compound of any one of embodiments 1 to 17, wherein R4is hydrogen, -F, or -Cl.
[0295] Embodiment 20. The compound of any one of embodiments 1 to 19, wherein R5is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
[0296] Embodiment 21. The compound of any one of embodiments 1 to 19, wherein R5is hydrogen, -F, -Cl, -I, or unsubstituted cyclopropyl.
[0297] Embodiment 22. The compound of any one of embodiments 1 to 21, wherein R6is substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0298] Embodiment 23. The compound of any one of embodiments 1 to 21, wherein R6is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted n-butyl, unsubstituted n-pentyl. unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted
[0299] Embodiment 24. The compound of any one of embodiments 1 to 23, wherein R7is substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0300] Embodiment 25. The compound of any one of embodiments 1 to 23, wherein R7is -CD3, unsubstituted methyl, unsubstituted ethyl, unsubstituted cyclopropyl,,
[0301] Embodiment 26. The compound of any one of embodiments 1 to 21, wherein R6and R7substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0302] Embodiment 27. The compound of any one of embodiments 1 to 21, wherein R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to
[0303] Embodiment 28. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0304] Embodiment 29. A method of treating a SARM1-associated disease in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt or solvate thereof.
[0305] Embodiment 30. The method of embodiment 29. wherein the SARM1-associated disease is a neurodegenerative disease.
[0306] Embodiment 31. The method of embodiment 30, wherein the neurodegenerative disease is Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, or chronic traumatic encephalopathy.
[0307] Embodiment 32. The method of embodiment 29. wherein the SARM1 -associated disease is an inflammatory disease.
[0308] Embodiment 33. The method of embodiment 32, wherein the inflammatory disease is multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, or psoriasis.
[0309] Embodiment 34. The method of embodiment 29, wherein the SARM1-associated disease is chemotherapy -induced peripheral neuropathy, diabetic neuropathy, Charcot-Marie-Tooth disease, stroke, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, hereditary’ neuropathy with liability' to pressure palsy, nerve entrapment, nerve crust due to trauma, alcoholic neuropathy, motor endplate myopathy, a muscle-wasting disease, glaucoma, autosomal dominant optic atrophy, a mitochondrial disease, traumatic brain injury’, a neurotrophic viral infection, or a bone disease.
[0310] Embodiment 35. The method of embodiment 34. wherein the Charcot-Marie-Tooth disease is CMT2 or CMT1.
[0311] Embodiment 36. The method of embodiment 29, wherein the SARM1-associated disease is a cancer.
[0312] Embodiment 37. A method of modulating SARM1 activity in a subject, said method comprising administering to the subject the compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt or solvate thereof.
[0313] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.EXAMPLES1. Experimental procedures and characterization data
[0314] Preparation of the compounds
[0315] The compounds used in the reactions described herein are made according to known organic synthesis techniques, starting from commercially available chemicals and / or from compounds described in the chemical literature. “Commercially available chemicals” are obtained from standard commercial sources including Acros Organics (Geel, Belgium), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Ark Pharm, Inc. (Libertyville, IL), Avocado Research (Lancashire, U. K ), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U. K.), Chemservice Inc. (West Chester, PA), Combi-blocks (San Diego, CA), Crescent Chemical Co. (Hauppauge, NY), eMolecules (San Diego, CA), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT). ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U. K.), Lancaster Synthesis (Windham, NH), Matrix Scientific, (Columbia, SC), Maybridge Chemical Co. Ltd. (Cornwall, U. K.), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Ryan Scientific. Inc. (Mount Pleasant, SC), Spectrum Chemicals (Gardena, CA), Sundia Meditech, (Shanghai, China), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and WuXi (Shanghai, China).
[0316] Suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, “Synthetic Organic Chemistry,” New York: John Wiley & Sons, Inc., 1982; Sandler S. R. et al., “Organic Functional Group Preparations,” 2nded., New York: Academic Press, 1983; House, H. O., “Modem Synthetic Reactions,” 2nded., Menlo Park: W. A. Benjamin, Inc., 1972; Gilchrist, T. L., “Heterocyclic Chemistry,” 2nded.,New York: Wiley, 1992; March, J, ‘‘Advanced Organic Chemistry: Reactions, Mechanisms and Structure,” 4thed., New York: Wiley, 1992. Additional suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J., Penzlin, G., “Organic Synthesis: Concepts, Methods, Starting Materials,” 2nded., New York: Wiley, 1994; Hoffman, R. V., “Organic Chemistry’, An Intermediate Text,” Oxford: Oxford University Press, 1996; Larock, R. C., “Comprehensive Organic Transformations: A Guide to Functional Group Preparations,” 2nded., New York: Wiley, 1999; Otera, J., “Modem Carbonyl Chemistry’,” New York: Wiley, 2000; Solomons, T. W. G.. “Organic Chemistry,” 7thed., New York: Wiley, 2000; Stowell, J. C., “Intermediate Organic Chemistry,” 2nded.. New York: Wiley. 1993; " Industrial Organic Chemicals:Starting Materials and Intermediates: An Ullmann’s Encyclopedia,” New York: Wiley, in 8 volumes; “Organic Reactions,” New York: Wiley, in over 55 volumes; and “Chemistry of Functional Groups,” New York: Wiley, in 73 volumes.
[0317] Specific and analogous reactants are also identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society’, Washington, D. C., may be contacted for more details). Chemicals that are known but not commercially available in catalogs are optionally prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g, those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is Stahl, P. H., Wermuth, C. G., “Handbook of Pharmaceutical Salts,” Zurich: Verlag Helvetica Chimica Acta, 2002.
[0318] List of abbreviations
[0319] As used above, and throughout the description of the invention, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:ACN or MeCN acetonitrileAcOH acetic acidaq aqueousBu butylBOC or Boc / e / 7-butyl carbamateBSA bovine serum albuminB2pin2 bis(pinacolato)diboronCDI 1, 1’ -carbonyldiimidazoleCHO Chinese hamster ovary7Cy cyclohexylDABCO L4-diazabicyclo[2.2. 2]octanedba di benzy li deneacetoneDCE dichloroethane (CICH2CH2CI)DCM dichloromethane (CH2CI2)DIPEA or DIEA AjV-diisopropylethylamineDMA 'V. A-di meth l acetami deDMAP 4-(AA-dimethylamino)pyridineDMF. VA'-di methyl formamideDMSO dimethylsulfoxideEDC A-(3-dimethylaminopropyl)-jV’ -ethylcarbodiimideequiv equivalent(s)Et ethylEtOH ethanolEtOAc ethyl acetateh hour(s)HATU l-[bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphateHEPES 4-(2-hydroxy ethyl)- 1 -piperazineethanesulfonic acidHex hexanesHPLC high performance liquid chromatographyLCMS or LC-MS liquid chromatography-mass spectrometryLDA lithium diisopropylamideLG leaving groupM molarMe methylMeOH methanolmin minute) s)MS mass spectroscopyMTBE methyl tert-butyl etherNIS jV-iodosuccinimideNMI. V-methylimidazoleNMP. V- methyl -2 -pyrrolidoneNMR nuclear magnetic resonancePd / C palladium on carbonPE petroleum etherPG protecting groupPyAOP (7-Azabenzotriazol-l-yloxy)tripyrrolidinophosphonium hexafluorophosphate)RT room temperatureT3P propylphosphonic anhydrideTBAF tetrabutylammonium fluorideTCFH chi oro-XjV. A’, N" -tetramethylformamidinium hexafluoro phosphate TEA triethylamineTFA trifluoroacetic acidTHF tetrahydrofuranTsCl 4-toluenesulfonyl chloridev / v volume per volumew / w weight per weightXPhos 2-dicyclohexylphosphino-2’4’6’-triisopropylbiphenyl XtalFluor-E (diethylamino)difluorosulfonium tetrafluoroborate
[0320] Examples
[0321] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for synthetic transformations sensitive to moisture and / or oxygen. Yields were not optimized. Reaction times are approximate and were not optimized. Column chromatography was performed on silica gel unless otherwise noted.
[0322] Intermediate acid 1: Preparation of 4-bromo-7-fluoro-5-methyl-17 / -indole-2-carboxylic acid.
[0323] Step 1: To a solution of 4-bromo-7-fluoro-5-methyl-lEf-indole (1.0 equiv) in DMF (0.4 M) at 0 °C under N2 atmosphere was added sodium hydride (1.1 equiv of a 60 wt.% dispersion in mineral oil). The resulting mixture was stirred at 0 °C for 0.5 h at which time p-toluenesulfonyl chloride (1.3 equiv) was added in portions over 10 min. The resulting mixture was allowed to warm to rt and for additional 3 h. The reaction mixture was poured into ice water and the resulting mixture was extracted with EtOAc (3x). The combined organic layers were washed with brine (2*), dried over anhydrous Na2SC>4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, [PE: DCM (10: 1 v / v)] to afford 4-bromo-7-fluoro-5-methyl-l-(4-methylbenzenesulfonyl)indole (31% yield) as a yellow solid.
[0324] Step 2: To a stirred solution of 4-bromo-7-fluoro-5 -methyl- 1 -(4-methylbenzenesulfonyl)indole (1.0 equiv) in THF (0.2 M) at -78 °C under N2 atmosphere was added LDA (1.2 equiv of a 2 M solution in THF). The resulting mixture was stirred at -78 °C for 0.5 h at which time ethyl chloroformate (1.2 equiv) was added dropwise over 15 minutes. The resulting mixture was stirred at -78 °C for additional 1 h, poured into an ice cooled solution of saturated NH4CI. The resulting mixture was extracted with EtOAc (3x). The combined organic layers were washed with brine (2x), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue w as purified by silica gel column chromatography, [PE: EtOAc (7: 1 v / v)] to afford ethyl 4-bromo-7-fluoro-5-methyl-1-tosyl-1H-indole-2-carboxylate (55% yield) as a white solid.
[0325] Step 3: To a stirred solution of 4-bromo-7-fluoro-5-methyl-l-tosyl-17f-indole-2-carboxylate (1.0 equiv) in THF / H2O / MeOH (1: 1: 1, 0.1 M) at rt was added NaOH (5 equiv). The mixture w as heated to 60 °C and stirred for 1 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was acidified to pH = 5 with concentrated HC1 and the residue was purified by reverse phase flash chromatography (C18 column, 5% ACN in water containing 0.1 % TFA gradient to 95% ACN in water containing 0.1 % TFA) which provided 4-bromo-7-fluoro-5-methyl- IW-indole-2-carboxylic acid (Intermediate acid 1, 81% yield) as a white solid.
[0326] Alternative synthesis of Intermediate acid 1:
[0327] Step 1: A mixture of 5-bromo-2-fluoro-4-methylaniline (1.0 equiv) and N-iodosuccinimide (1.1 equiv) in acetic acid (0.35 M) was stirred at rt for 1 h. The mixture was concentrated under reduced pressure and partitioned between EtOAc and saturated aq. NaHCOs. The layers were separated and the aqueous phase was back-extracted with EtOAc (2x). The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The concentrate was treated with heptane to precipitate a white solid. The mixture was filtered and the filtrates were concentrated under reduced pressure and purified by silica gel column chromatography, [hexanes gradient to hexanes / DCM (1: 1.5 v / v)] to afford 3-bromo-6-fluoro-2-iodo-4-methylaniline (79% yield) as light red solid.
[0328] Step 2: A mixture of 3-bromo-6-fluoro-2-iodo-4-methylaniline (1.0 equiv). pyruvic acid (3.0 equiv), 4-diazabicyclo[2.2. 2]octane (3.0 equiv), and Pd(OAc)2 (0.075 equiv) in DMF (0.3 M) were heated via microwave irradiation at 120 °C for 2.5 h. The mixture was cooled to rt and partitioned between aqueous HC1 (2 M) and EtOAc. The phases were separated and the aqueous phase was back-extracted with EtOAc. The combined organics were washed sequentially with aqueous HC1 (2 M) and brine. The organics were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, [hexanes: EtOAc (3: 1 v / v gradient to 1: 1 v / v)] to afford a white solid which contained 4-bromo-7-fluoro-5-methyl-l / f-indole-2-carboxylic acid (67 wt.%, Intermediate acid 1, 33% yield) and 7-fluoro-5-methyl-l / / -indole-2-carboxylic acid (23% yield).
[0329] Intermediate acid 2: Preparation of7-fluoro-5-methyl-4-(l-methyl-lE7-l,2,4-triazol-3-yl)-lE7-indole-2-carboxylic acid.
[0330] Step 1: A solution of 4-bromo-7-fluoro-5-methyl-l-tosyl-17f-indole-2-carboxylate (1.0 equiv), prepared as described for the synthesis of Intermediate acid 1 step 3, 1-methyl-3-(tributylstannyl)-1.2.4-triazole (1.2 equiv), and Pd(t-Bu3P)2 (0.2 equiv) in DMF (0.1 M) was stirred at 120 °C for 1 h under nitrogen atmosphere. The mixture cooled to rt and purified by reverse phase flash chromatography (C18 column, 1% ACN in water containing 10 mmol / L (NH-OHCCh gradient to 95% ACN in water containing 10 mmol / L (NH₄)HCO₃) which provided ethyl 7-fluoro-5-methyl-4-(l-methyl-l / 7-l,2,4-triazol-3-yl)-l-tosyl-177-indole-2-carboxylate (87% yield) as a white solid.
[0331] Step 2: Intermediate acid 2 was prepared from ethyl 7-fluoro-5-methyl-4-(l-methyl-l / 7-l,2,4-triazol-3-yl)-l-tosyl-177-indole-2-carboxylate in similar fashion as described for the synthesis of Intermediate acid 1, step 3 with the exception that EtOH was substituted for MeOH. 7-fluoro-5-methyl-4-(l-methyl-177-l,2,4-triazol-3-yl)-127-indole-2-carboxylic acid (31% yield) was obtained as an off-white solid.
[0332] Intermediate acid 3: Preparation of 7-fluoro-5-methy l-4-(l -methyl- \H- 1,2,4-triazol-3-yl)-l-tosyl-177-indole-2-carboxylic acid.
[0333] To a solution of ethyl 7-fluoro-5-methyl-4-(l -methyl- \H- 1, 2,4-triazol-3-yl)-l -tosyl-l / / -indole-2-carboxylate prepared as described for the synthesis of Intermediate acid 2, step 1 (1.0 equiv) in THF / EtOH / H2O (1: 1: 1, 0.06 M) at 0 °C was added LiOH (5.0 equiv). The resulting mixture was stirred at rt for 7 h, acidified to pH ~1 with aqueous HC1 (2 M), and extracted with EtOAc (2x). The organics were dried over Na2SO4, filtered, and concentratedunder reduced pressure to afford 7-fluoro-5-methyl-4-(l-methyl-17f-l,2,4-triazol-3-yl)-l-tosyl-17 / -indole-2-carboxylate (Intermediate acid 3, 60% yield) as a yellow solid.
[0334] Intermediate acid 4: Preparation of 4-bromo-5-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-177-indole-2-carboxylic acid.
[0335] Step 1: To a solution of ethyl 4-bromo-5-chloro-17 / -indole-2-carboxylate (1.0 equiv) in DMF (0.1 M) cooled to 0 °C was added NaH (2.0 equiv). The mixture was stirred for 30 min at which time. [2-(chloromethoxy)ethyl]trimethylsilane (1.5 equiv) was added and the resultant mixture was stirred for 1 h while warming to rt. The reaction was quenched with sat. NH4C1 (aq.) extracted with EtOAc. The organics were washed with water, dried over Na2SOr, filtered, and concentrated under reduced pressure. Purification by silica gel column chromatography (PE: EtOAc) gave ethyl 4-bromo-5-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-l / 7-indole-2-carboxylate (58% yield) as a colorless oil.
[0336] Step 2: To a stirred solution of ethyl 4-bromo-5-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-lE7-indole-2-carboxylate (1.0 equiv) in THF / MeOH / EEO (1: 1: 1, 0.1 M) at rt was added NaOH (3.0 equiv). The resulting mixture was stirred at room temperature for 1 h and acidified to pH ~4 with cone. HC1. The mixture was extracted with EtOAc and the organics were washed with water, dried over Na2SO4. filtered, and concentrated under reduced pressure which provided 4-bromo-5-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)- IH-indole-2-carboxylic acid (Intermediate acid 4, 89% yield) as a white solid.
[0337] Intermediate acid 5: Preparation of 4-bromo-5-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)- 177-mdole-2-carboxy I ic acid.
[0338] A solution of methyl 4-chl oro-5 -(trifluoromethyl)- l / / -indole-2-carbox late (1.0 equiv) and LiOH (3.0 equiv) in THF / H2O (1: 1, 0.2 M) was stirred at rt for 1 h and concentrated in vacuo. The crude product was used without further purification.
[0339] Intermediate acid 6: Preparation of 4-bromo-5-chloro-7-fluoro-lH-indole-2-carboxylic acid.
[0340] Step 1: Iodination of 5-bromo-4-chloro-2-fluoroaniline was performed in similar fashion as described for the alternative synthesis of Intermediate acid 1 step 1, which gave 3-bromo-4-chloro-6-fluoro-2-iodoaniline (74% yield) as a brown solid.
[0341] Step 2: To a solution of 3-bromo-4-chloro-6-fluoro-2 -iodoaniline (1.0 equiv) and trimethylsilylacetylene (1.2 equiv), and triethylamine / DMF (1: 1, 0.15 M) was added Cui (0.10 equiv) and dichlorobis(triphenylphosphine)palladium(II) (0.10 equiv) at rt. The mixture was heated and stirred at 100 °C for 17 h under nitrogen atmosphere. The mixture was cooled to rt and partitioned between EtOAc and water. The phases were separated and the organics were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography, [PE: EtOAc (10: 1 v / v)] to afford 3-bromo-4-chloro-6-fluoro-2-((trimethylsilyl)ethynyl)aniline (51% yield) as a brown solid.
[0342] Step 3: A mixture of 3-bromo-4-chloro-6-fluoro-2-((trimethylsilyl)ethynyl)aniline (1.0 equiv) and Cui (2.0 equiv) in DMF (0.3 M) was stirred at 100 °C for 17 h under nitrogen atmosphere. The mixture was cooled to rt and partitioned between EtOAc and water. The phases w ere separated and the organics were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography, [PE:EtOAc (10: 1 v / v)] to afford 4-bromo-5-chloro-7-fluoro-177-indole (36% yield) as a brown solid.
[0343] Step 4: The tosylation reaction was performed in similar fashion as described for the synthesis of Intermediate acid 1 step 1, which gave 4-bromo-5-chloro-7-fluoro-l-tosyl-177-indole (68% yield) as a brown solid.
[0344] Step 5: Performed in similar fashion as described for the synthesis of Intermediate acid 1 step 2, which gave ethyl 5-bromo-4-chloro- l-tosyl- IH-indole-2-carboxylate (32% yield) as a brown solid.
[0345] Step 5: The hydrolysis reaction was performed as described for the synthesis of Intermediate acid 1 step 3, which gave 4-bromo-5-chloro-7-fluoro-l / f-indole-2-carboxylic acid (Intermediate acid 6, 55% yield) as a white solid.
[0346] Intermediate acid 7: Preparation of 4-chloro-5-cyano-lE7-indole-2-carboxylic acid.
[0347] Step 1: Performed in similar fashion as described for the synthesis of Intermediate acid 1 step 2, which gave ethyl 4-bromo-5-chloro-7-fluoro-l-tosyl-177-indole-2-carboxylate (55% yield) as a white solid.
[0348] Step 2: To a solution of ethyl 5-bromo-4-chl oro-1 -tosyl- lf / -indole-2-carboxy late (1.0 equiv) and Pd(PPhs)4 (0.1 equiv) in DMF (0.08 M) was added Zn(CN)? (2.0 equiv) at rt. The mixture was stirred and heated at 130 °C for 16 h under nitrogen atmosphere. The mixture was cooled to rt and partitioned between EtOAc and water. The phases were separated and the organics were washed with brine, dried over Na2SC>4. filtered, and concentrated. The residue was purified by silica gel column chromatography, [PE: EtOAc (8: 1 v / v)] to afford ethyl 4-chloro-5-cyano-l-tosyl-lH-indole-2-carboxylate (25% yield) as a white solid.
[0349] Step 3: To a stirred solution of ethyl 4-chloro-5-cyano-l-tosyl-lE7-indole-2-carboxylate (1.0 equiv) in THF / H2O (1: 1, 0.04 M) was added LiOH (4.0 equiv) at roomtemperature. The mixture was heated to 60 °C for 4 h. cooled to rt, and acidified to pH ~3 with concentrated HC1. Purification by reverse phase flash chromatography (C18 column, 10% ACN in water containing 0.1% TFA gradient to 50% ACN in water containing 0.1% TFA) provided 4-chloro-5-cyano-lH-indole-2-carboxylic acid (Intermediate add 7, 75% yield) as a white solid.
[0350] Intermediate acid 8: Preparation of 5-methyl-4-(l -methyl- 1 / / - 1.2.4-triazol-3-yl)-H7-indole-2-carboxylic acid.Intermediateacid 8
[0351] Step 1: To a solution of 4-bromo-5-methyl-777-indole (1.0 equiv) in DCM (0.02 M) at rt was added sequentially NaOH (10.0 equiv), tetrabutylammomum hydrogen sulfate (0.10 equiv) and TsCl (1.2 equiv). The mixture was stirred at rt for Ih and washed with water. The organic phase was washed with water, dried over Na2SC>4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, [PE: EtOAc (1: 1 v / v)] to afford 4-bromo-5-methyl-l-tosyl-17f-indole (62% yield) as a white solid.
[0352] Step 2: Performed in similar fashion as described for the synthesis of Intermediate acid 1 step 2, which gave ethyl 4-bromo-5 -methyl- 1 -tosyl- 17f-indole-2-carboxylate (68% yield) as a yellow solid.
[0353] Step 3: The coupling reaction was performed in similar fashion as described for the synthesis of Intermediate acid 2 step 1, which gave ethyl 5-methyl-4-(l-methyl-l / 7-l,2,4-triazol-3-yl)-l-tosyl-177-indole-2-carboxylate (82% yield) as ayellow oil.
[0354] Step 4: The hydrolysis reaction was performed as described for the synthesis of Intermediate acid 1 step 3, which gave the title compound (Intermediate acid 8).
[0355] Intermediate acid 9: Preparation of 4-(5-fluoropyrimidin-2-yl)-5-methyl-l-tosyl-H7-indole-2-carboxylic acid.Intermediateacid 9
[0356] Step 1: A mixture of ethyl 4-bromo-5-methyl-l-tosyl-17 / -indole-2-carboxylate (1.0 equiv) and bis(pinacolato)diboron (1.5 equiv), K2CO3 (3.0 equiv) and Pd(PPha)4 (0.1 equiv) in dioxane (0.2 M) was stirred at 80°C under a nitrogen atmosphere for 24 h at which time the mixture was cooled to rt and partitioned between water and EtOAc. The organic phase was washed with water, dried over Na2SC>4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, [PE: EtOAc (5: 1 v / v)] to afford ethyl 5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-tosyl-lH-indole-2-carboxylate (65% yield) as a white solid.
[0357] Step 2: A mixture of ethyl 5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l -tosyl- 177-indole-2-carboxylate (1.0 equiv), 2-bromo-5-fluoropyrimidine (1.50 equiv), and K2CO3 (3.0 equiv), and Pd(PPh3)4 (0.1 equiv) in dioxane / H₂O (5: 1, 0.1 M) was stirred at 90 °C for 24 h under nitrogen atmosphere at which time the mixture was cooled to rt and partitioned between water and EtOAc. The organic phase was washed with water, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography. [PE: EtOAc (5: 1 v / v)] to afford ethyl 4-(5-fluoropyrimidin-2-yl)-5-methyl-l-tosyl-l / f-indole-2-carboxylate (71% yield) as a white solid.
[0358] Step 3: To a stirred solution of ethyl 4-(5-fluoropyrimidin-2-yl)-5-methyl-l-tosyl-lH-indole-2-carboxylate (1.0 equiv) in THF / MeOEI / EhO (1: 1: 1, 0.05 M) was added LiOH (5.0 equiv). The mixture was heated to 45 °C and stirred for 2 h. The resulting mixture was cooled to rt, concentrated under reduced pressure, and acidified to pH ~5 with concentratedHC1. Purification by reverse phase flash chromatography (C18 column, 5% ACN in water containing 0.1% TFA gradient to 95% ACN in water containing 0.1% TFA) provided the title compound (Intermediate acid 9, 86% yield) as a white solid.
[0359] Intermediate acid 10: Preparation of 7-fluoro-5-methyl-4-(l,2,4-triazin-3-yl)-lH-indole-2-carboxylic acid.
[0360] Step 1: A mixture of ethyl 4-bromo-7-fluoro-5-methyl-l-tosyl-lE7-indole-2-carboxylate (1.0 equiv), bis(pinacolato)diboron (5 equiv), Pd(dppf)C12 DCM (0.1 equiv), and K3PO4 (4.0 equiv) in dioxane (0.15 M) was stirred at 100 °C for 16 h under nitrogen atmosphere. The mixture was cooled to rt and filtered. The filter cake was washed with MeOH (3 x) and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, [PE: EtOAc (12: 1 v / v)] to afford ethyl 7-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-tosyl-177-indole-2-carboxylate (88% yield) as a white solid.
[0361] Step 2: A solution of ethyl 7-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-tosyl-lE7-indole-2-carboxylate (1.0 equiv), NaKfi (5.0 equiv), and NH4OAC (5.0 equiv) in acetone: H2O (1: 1, 0.1 M) was stirred at 70 °C for 16 h. The mixture was cooled to rt. filtered, and the filter cake was washed with MeOH (3x). The filtrate was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography (C18 column, 10% ACN in water containing 0.1% TFA gradient to 50% ACN in water containing 0.1% TFA) which provided 2-(ethoxycarbonyl)-7-fluoro-5-methyl-l-(4-methylbenzenesulfonyl)indol-4-ylboronic acid (49% yield) as a white solid.
[0362] Step 3: A mixture of (2-(ethoxycarbonyl)-7-fluoro-5-methyl-l-tosyl-17f-indol-4-yl)boronic acid (1.0 equiv), 3 -(methylthio)- 1, 2, 4-triazine (1.5 equiv), CuMeSal (2.2 equiv), and Pd(PPh3)4 (0.1 equiv) in THF (0.1 M) was stirred at 70 °C for 2 h under nitrogen atmosphere. The mixture was cooled to rt filtered. The filter cake was washed with THF (3x) and the filtrates were concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (C18 column, 10% ACN in water containing 10 mmol / L (NH4)HCOS gradient to 50% ACN in water containing 10 mmol / L (NH4)HCO3) which gave ethyl 7-lluoro-5-methyl- 1 -tosyl-4-( 1.2.4-triazm-3-yl)- 17 / -mdole-2-carboxylate (35% yield) as a white solid.
[0363] Step 4: The hydrolysis reaction was performed as described for the synthesis of Intermediate acid 1 step 3, with the exception that MeOH was substituted for EtOH, which gave the title compound (Intermediate acid 10, 95% yield) as a white solid.
[0364] Intermediate acid 11: Preparation of 4-chloro-7-fluoro-5-methyl-l / 7-indole-2-carboxylic acid.Intermediate acid 11
[0365] Step 1: A mixture of 5-chloro-2-fluoro-4-methylaniline (1.0 equiv) and N-iodosuccinimide (1.3 equiv) in acetic acid (0.5 M) was heated to 50 °C for 4 h. The mixture was cooled to rt and concentrated under reduced pressure. The mixture was partitioned between EtOAc and 5% aqueous sodium chloride. The layers were separated and the organics were washed with a 1: 1 mixture of 5% aqueous sodium thiosulfate: 5% aqueous sodium bicarbonate, followed by brine. The organics were dried over MgSCL, filtered, and concentrated under reduced pressure to provide the product, 3-chloro-6-fluoro-2-iodo-4-methylaniline, as a brown residue that was used directly in the next reaction.
[0366] Step 2: A mixture of 3-chloro-6-fluoro-2-iodo-4-methylaniline from step 1, pyruvic acid (3.0 equiv), 4-diazabicyclo[2.2. 2]octane (3.0 equiv). and Pd(OAc)2 (0.10 equiv) in DMF (0.2 M) was 120 °C for 14 h. The mixture was cooled to rt, partitioned between aqueous HC1 (1 M) and EtOAc, and filtered. The filtrate phases were separated and the organics were washed with 5% aqueous LiCl. The organics were dried over MgSO4, filtered, andconcentrated under reduced pressure. The residue was purified by silica gel column chromatography, [hexanes: EtOAc (1: 0 v / v gradient to 1: 2 v / v)] to afford 4-chloro-7-fluoro-5-methyl-lH-indole-2-carboxylic acid, Intermediate acid 11, as a white solid (70% yield).
[0367] Alternative synthesis of Intermediate acid 2 from Intermediate acid 11:
[0368] Step 1: In a round-bottom flask equipped with a magnetic stirrer was combined Intermediate acid 11 (1.0 equiv) and toluene (0.8 M). The flask was equipped with a reflux condenser and heated to 110 °C, then N, N-dimethyl(di-tert-butoxymethyl)amine (3.0 equiv) was added dropwise. Stirring was continued at 110 °C for 30 min, the reaction was cooled to rt and stirred for an additional 5 h. The reaction was diluted wi th MTBE and the organics were washed sequentially with aqueous 10% aqueous sodium bicarbonate and aqueous 10 wt.% aqueous NaCl solution. The combined organics were dried over MgSCE. filtered, and the filtrate concentrated in vacuo to deliver tert-butyl 4-chloro-7-fluoro-5-methyl-lH-indole-2-carboxylate as a dark brown powder (83% yield).
[0369] Step 2: In a sealed reaction vessel equipped with a magnetic stirrer was combined tert-butyl 4-chloro-7-fluoro-5-methyl-lH-indole-2-carboxylate from step 1 (1.0 equiv), 1-methyl-3-(tributylstannyl)-lH-l,2,4-triazole (1.2 equiv), XPhos Pd G3 MTBE complex (0.2 equiv), and DMF (0.25M). The flask was sealed, heated to 120 °C, and stirred overnight. After cooling to rt, the reaction was diluted with aqueous 1 M KF solution and vigorously stirred for 20 minutes. The mixture was filtered through a bed of Celite, eluted with EtOAc, and the filtrate was extracted into EtOAc. The organic extracts were washed with 10 wt% aqueous LiCl solution, dried over MgSO4, filtered, and the filtrate concentrated in vacuo.Purification by column chromatography (silica gel, gradient elution:75% EtOAc / hexanes) afforded / e / 7-butyl 7-fluoro-5-melhyl-4-(l-methyl-l7 / -l.2.4-triazol-3-yl)-l / / -indole-2-carboxylate (72% yield).
[0370] Step 3: In a round-bottom flask equipped with a magnetic stirrer was combined / e / 7-butyl 7-fluoro-5-methyl-4-(l-methyl-177-l,2,4-triazol-3-yl)-17 / -indole-2-carboxylate from step 2 (1.0 equiv) and DCM (0.2 M). The solution was cooled to 0 °C and trifluoracetic acid (65 equiv) was added dropwise. Stirring was continued at 0 °C for 30 minutes, then the reaction was warmed to rt and stirred a further 90 minutes. The volatiles were removed by concentration in vacuo, and the crude residue was diluted with DCM followed by reconcentration in vacuo. A solution of 1 N aqueous NaOH (approx. 1.0 equiv) was added to the residue and the mixture was further diluted with water and extracted with DCM:Isopropanol (5: 1, 3x). The combined organics were dried over MgSCh, filtered, and concentrated to deliver Intermediate acid 2 as a brown powder (51% yield).
[0371] Intermediate acid 12: Preparation of 4-bromo-5-methoxy-17 / -indole-2-carboxylic acid.Intermediateacid 12
[0372] The hydrolysis of ethyl 4-bromo-5-methoxy- IT / -indole-2 -carboxylate was performed as described for the synthesis of Intermediate acid 1 step 3, with the exception that MeOH was substituted for EtOH, which gave the title compound (Intermediate acid 12, 77% yield) as a white solid.
[0373] Intermediate acid 13: Preparation of 5-(difluoromethyl)-4-(l-methyl-177-l,2,4-triazol-3-yl)-l-tosyl-17 / -indole-2-carboxylic acid.
[0374] Step 1: A mixture of ethyl 5-bromo-4-chloro-l-tosyl-17Mndole-2-carboxylate (1.0 equiv), obtained as described for the synthesis of Intermediate acid 7, step 1, tributyl(vinyl) tin (1.1 equiv), Pd(PPh3)2C12 (0.10 equiv) and DMF (0.1 M) was heated and stirred at 90°C in a sealed reaction vessel for 18 h. The mixture was cooled to rt and partitioned between EtOAc and H2O. The organics were washed with water (2x), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with PE / EA (15%) to afford ethyl 4-chloro-l-tosyl-5-vinyl-17 / -indole-2-carboxylate (81% yield) as a white solid.
[0375] Step 2: A mixture of ethyl 4-chloro-l-tosyl-5-vinyl-17 / -indole-2-carboxylate from step 1 (1.0 equiv), OsO4 (0.35 equiv), NaIO4 (5.0 equiv), acetone (0.2 M) and H2O (0.7 M) was stirred at rt for 1 h. The mixture was partitioned between EtOAc and H2O. The organics were washed with water (2x), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo which gave ethyl 4-chloro-5-formyl-l-tosyl- lH-indole-2-carboxylate white solid.Material was used directly in the next reaction (step 3).
[0376] Step 3: Into a sealed tube were added ethyl 4-chloro-5-formyl-l-tosyl-lH-indole-2-carboxylate from step 2 (1.0 equiv), DAST (75.0 equiv) and DCM (0.02 M). The mixture was stirred at 45 °C for 5 h under nitrogen atmosphere, then partitioned between EtOAc and H2O. The organics were washed with water (2x), dried over anhydrous Na2SO4,, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with EA / PE (20%) to afford ethyl 4-chloro-5-(difluoromethyl)-l-tosyl-lEf-indole-2-carboxylate (65% yield, two steps) as a yellow solid.
[0377] Step 4: The Stille coupling of ethyl 4-chloro-5-(difluoromethyl)-l-tosyl-177-indole-2-carboxylate from step 4 and I -methyl-3-(tributylstannyl)-IH-l,2.4-tnazole was performedin similar fashion as described for the synthesis of Intermediate acid 2 step 1, which gave ethyl 5-(difluoromethyl)-4-(l -methyl- IH- 1, 2, 4-triazol-3-yl)-l -tosyl- 177-indole-2-carboxylate as a white solid (53% yield).
[0378] Step 5: The hydrolysis of ethyl 5-cyclopropyl-4-(l -methyl- 177- 1,2,4-tri azol -3-yl)- 1 -tosyl-lEf-indole-2-carboxylate from step 2 was performed as described for the synthesis of Intermediate acid 9 step 3, with the exception that MeOH was substituted for EtOH, which gave the title compound (Intermediate acid 13) as a white solid (44% yield).
[0379] Intermediate acid 14: Preparation of 4-chloro-5-(trifluoromethoxy)-17f-indole-2-carboxylic acid.
[0380] Step 1: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 1 to give 3-chloro-2-iodo-4-(trifluoromethoxy)aniline as a brown oil (21% yield).
[0381] Step 2: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 to give the title compound. Intermediate acid 14. as a brow n solid (68% yield).
[0382] Intermediate acid 15: Preparation of 4-bromo-7-chloro-5-methyl-lH-indole-2-carboxylic acid.Intermediate acid 15
[0383] Step 1: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 1 to give 3-bromo-6-chloro-2-iodo-4-methylaniline as a brown oil (83% yield).
[0384] Step 2: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 to give the title compound. Intermediate acid 15. as a brown solid (16% yield).
[0385] Intermediate acid 16: Preparation of 4-bromo-5-(difluoromethoxy)-7-fluoro-lH-indole-2-carboxylic acid.Intermediateacid 16
[0386] Step 1: To a mixture of l-bromo-2-(difluoromethoxy)-4-fluoro-5-nitrobenzene (1.0 equiv) and Fe (5.0 equiv) in EtOH: H2O (1: 1, 0.25 M) was added NH4CI (5.2 equiv). The resulting mixture was stirred at 80 °C for 18 h under nitrogen atmosphere. The mixture cooled to rt, filtered, the filter cake was washed with EtOAc (3x). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with PE / EA (4:1) to afford 5-bromo-4-(difluoromethoxy)-2-fluoroaniline (62%) as yellow oil.
[0387] Step 2: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 1 to give 3-bromo-4-(difluoromethoxy)-6-fluoro-2 -iodoaniline as a brown semi-solid (31% yield).
[0388] Step 3: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 to give the title compound, Intermediate acid 16, as a brown solid (73% yield).
[0389] Intermediate acid 17: Preparation of 4-bromo-7-fluoro-5-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)- 1 / 7-indole-2-carboxy I ic acid.Intermediateacid 17
[0390] Step 1: To a stirred solution of 4-bromo-7-fluoro-5 -methyl- l / f-indole-2-carboxy lie acid (Intermediate acid 1, 1.0 equiv) in MeOH (0.25 M) was added SOCl₂ (2.0 equiv) dropwise at rt. The resulting mixture was stirred at room temperature for 20 h. The reaction was cooled to 0 °C and quenched by the careful addition of sat. aqueous NaHCO₃. The mixture was warmed to rt and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SC>4. filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with PE / EA to afford methyl 4-bromo-7-fluoro-5-methyl-17f-indole-2-carboxylate (68% yield) as a brown solid.
[0391] Step 2: To an ice cooled solution of methyl 4-bromo-7-fluoro-5-methyl-177-indole-2-carboxylate from step 1 (1.0 equiv) in DMF (0.3) was added NaH (3.0 equiv). The resulting mixture was stirred at 0 °C for 30 min under nitrogen atmosphere at which time SEMC1 (1.5 equiv) was added dropwise. The resulting mixture was stirred at 0 °C for an additional 2 h at which time the mixture was quenched by the addition of sat. aqueous NH4CI. The mixture was extracted with EtOAc (3x) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with PE / EA (1: 1) to afford methyl 4-bromo-7-fluoro-5-methyl-l-([2-(trimethylsilyl)ethoxy]methylindole-2 -carboxylate (70% yield) as a brown solid.
[0392] Step 3: The hydrolysis was performed as described previously for the synthesis of Intermediate acid 13. step 5, which gave the title compound (Intermediate acid 17, 89% yield) as a brown powder.
[0393] Intermediate acid 18: Preparation of 7-fluoro-5-methyl-4-(l-methyl-l / 7-l,2,4-triazol-3-yl)-l -((2-(trimethylsilyl)ethoxy)methyl)- IH-indole-2-carboxylic acid.
[0394] Step 1: The reaction was performed in analogous fashion as described in the synthesis of Intermediate acid 17, step 1 to provide methyl 4-chloro-7-fluoro-5 -methyl- H-indole-2-carboxylate.
[0395] Step 2: The Stille coupling of methyl 4-chloro-7-fluoro-5-methyl-l / / -indole-2-carboxylate from step 1 and 1 -methyl-3-(tributylstannyl)-177-l,2,4-triazole was performed as described for the alternative synthesis of Intermediate acid 2 from Intermediate acid 11, step 2 to provide methyl 7-fluoro-5-melhyl-4-(l-methyl-17f-l,2,4-triazol-3-yl)-17f-indole-2-carboxylate (68% yield).
[0396] Step 3: The SEM-protection was performed as described previously for the synthesis of Intermediate acid 17, step 2 to provide methyl 7-fluoro-5-methyl-4-(l-methyl-17 / -l,2,4-triazol-3-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lE7-indole-2-carboxylate. The crude material was used directly in the next reaction (step 4).
[0397] Step 4: The hydrolysis was performed as described previously for the synthesis of Intermediate acid 13, step 5 to provide the title compound (Intermediate acid 18, 84% two-step yield) as a white solid.
[0398] Intermediate acid 19: Preparation of 4-chloro-7-fluoro-5-(trifluoromethyl)-177-indole-2-carboxylic acid.
[0399] Step 1: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 1 to give 3-chloro-6-fluoro-2-iodo-4-(trifluoromethyl)aniline as a yellow oil (50% yield).
[0400] Step 2: Performed in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 to give the title compound, Intermediate acid 19, as a brown solid (53% yield).
[0401] Intermediate acid 20: Preparation of 4-chloro-5-cyclopropyl-7-fluoro-17 / -indole-2-carboxylic acid.
[0402] Stepl: To a round bottom flask equipped with a reflux condenser containing 4-bromo-5 -chi oro-2 -fluoroaniline (1.0 equiv), cyclopropylboronic acid (1.3 equiv). CS2CO3 (2.5 equiv), and Pd(dppf)C12DCM (0.05 equiv) was added dioxane: water (3: 1, 0.5 M). The reaction vessel w as heated to 100 °C for 19 h. The mixture w as cooled to rt and filtered through celite. The filtrate was partitioned between MTBE and water. The phases were separated and the organics were washed with 10% aqueous NaCl, dried over Na2SO4, filtered and concentrated in vacuo. Purification by silica gel chromatography (0% EtOAc in hexanes gradient to 50% EtOAc in hexanes) gave 5-chloro-4-cyclopropyl-2-fluoroaniline as a red liquid (79% yield).
[0403] Step 2: To an ice-cooled solution of 5-chloro-4-cyclopropyl-2-fluoroaniline (1.0 equiv) from step 1 in AcOH (0.04 M) was added NIS (1.0 equiv) portion- wise over 15 min. The ice batch was removed and the mixture was stirred and additional 10 mm at which time the mixture was partitioned between EtOAc and H2O. Solid K2CO3 was added carefully until pH ~9 was reached. The phases were separated and the organics were w ashed with brine,dried over MgSC, filtered, and concentrated to a brown oil that was used directly in the next reaction (step 3).
[0404] Step 3: The palladium-catalyzed in indole formation was carried out on 3-chloro-4-cyclopropyl-6-fluoro-2-iodoaniline (from step 2) and pyruvic acid in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 which gave the title compound, Intermediate acid 20, as a brown solid (28% yield).
[0405] Intermediate acid 21: Preparation of 4-chloro-5-ethyl-7-fluoro-lE7-indole-2-carboxylic acid.
[0406] Step 1: A mixture of 4-bromo-5-chloro-2-fluoroaniline (1.0 equiv), potassium trifluoro(vinyl)borate (1.3 equiv), K3PO4 (3.0 equiv), and Pd(dppf)Ch DCM (0.1 equiv) in dioxane: water (20: 1, 0.6 M) heated to 80 °C and stirred for 3 h under nitrogen atmosphere. The mixture was cooled to rt and partitioned between EtOAc and water. The aqueous phase was back-extracted with EtOAc (2x) and the combined organics were washed with brine (3x), dried over Na₂SO₄ filtered and concentrated in vacuo. Purification by silica gel chromatography (50% EtOAc in hexanes) gave 5-chloro-2-fluoro-4-vinylaniline as a brown oil (93% yield).
[0407] Step 2: A mixture of 5-chloro-2-fluoro-4-vinylaniline from step 1 and 10% palladium on carbon (0.2 equiv) in EtOAc (0.08 M) was stirred under hydrogen atmosphere for Ih. The mixture was filtered through celite and concentrated in vacuo which gave 5-chloro-4-ethyl-2-fluoroaniline as a crude oil that was used directly in the next reaction (step 3).
[0408] Step 3: The iodination of 5-chloro-4-ethyl-2 -fluoroaniline from step 2 was performed as described previously for the alternative synthesis of intermediate acid 1, step 1.Purification by gave silica gel chromatography (50% EtOAc in hexanes) gave 3-chloro-4-ethyl-6-fluoro-2-iodoaniline as a white solid (48% yield, two steps).
[0409] Step 4: The palladium-catalyzed in indole formation was carried out on 3-chloro-4-ethyl-6-fluoro-2-iodoaniline (from step 3) and pyruvic acid in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 which gave the title compound, Intermediate acid 21, as a white solid (18% yield).
[0410] Intermediate acid 22: Preparation of (rac)-4-chloro-5-(2.2-difluorocyclopropyl)-7-fluoro-177-indole-2-carboxylic acid.
[0411] Step 1: To a solution of 4-bromo-5-chloro-2-fluoroaniline (1.0 equiv) in PhMe (0.3 M) was added 2,5 -hexanedione (5.00 equiv) and TsOH (0.30 equiv) at rt. The resulting mixture was stirred at 100 °C for 1 h under nitrogen atmosphere. The reaction was cooled to rt and quenched with sat. aqueous NaHCO₃h. The resulting mixture was extracted with EtOAc (3x). The combined organic layers were dried over anhydrous NazSC, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with PE / EA (20:1) to afford l-(4-bromo-5-chloro-2-fluorophenyl)-2,5-dimethyl-l / 7-pyrrole (83% purity) as a brown solid.
[0412] Step 2: The Pd-catalyzed coupling of l-(4-bromo-5-chloro-2-fluorophenyl)-2,5-dimethyl- 1 / / -pyrrole from step 1 and potassium trifluoro(vinyl)borate was carried out asdescribed for the synthesis Intermediate acid 21 which gave l-(5-chloro-2-fluoro-4-vinylphenyl)-2,5-dimethyl-l / 7-pyrrole (61% yield) as a brown oil.
[0413] Step 3: To a solution of l-(5-chloro-2-fluoro-4-vinylphenyl)-2,5-dimethyl-17f-pyrrole (1.0 equiv) from step 1 in PhMe (0.3 M) was added(bromodifl uoromethyl)trimethylsilane (2.0 equiv) and TBAB (0.1 equiv) at rt. The mixture was stirred at 110 °C for 18 h under nitrogen atmosphere. The mixture was cooled to rt and partitioned between EtOAc and H2O. The phases were separated and the aqueous phase was back-extracted with EtOAc (2x). The combined organics were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash chromatography (C18 column, 5% ACN in water containing 10 mmol / L (NH^HCOs gradient to 95% ACN in water containing 10 mmol / L (NFLlHCCL) which gave l-(5-chloro-4-(2,2-difluorocyclopropyl)-2-fluorophenyl)-2,5-dimethyl-l / / -pyrrole (33% yield) as yellow oil.
[0414] Step 4: To a solution of l-(5-chloro-4-(2,2-difluorocyclopropyl)-2-fluorophenyl)-2,5-dimethyl-lH-pyrrole (1.0 equiv) from step 1 in EtOH (0.2 M) at rt was added NH2OH HCI (30.0 equiv) and H2O (1.0 M). The mixture was heated to 80 °C and stirred for 2 d under nitrogen atmosphere. The mixture cooled to rt, diluted with brine and extracted with EtOAc (3x). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with PE / EA (9:1) to afford 5-chloro-4-(2,2-difluorocyclopropyl)-2-fluoroaniline (59% yield) as purple oil.
[0415] Step 5: The iodination of 5-chloro-4-(2,2-difluorocyclopropyl)-2-fluoroaniline from step 4 was carried out in similar fashion as described for the synthesis of Intermediate acid 20, step 2 which gave 3-chloro-4-(2,2-difluorocyclopropyl)-6-fluoro-2-iodoaniline (79% yield) as a brown oil.
[0416] Step 6: The palladium-cataly zed in indole formation w as carried out on 3-chloro-4-(2, 2-difluorocyclopropyl)-6-fluoro-2 -iodoaniline (from step 5) and pyruvic acid in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 which gave the title compound. Intermediate acid 22, as a brown oil (20% yield).
[0417] Intermediate acid 23: Preparation of 4-chloro-7-fluoro-5-(2,2,2-trifluoroethyl)-177-indole-2-carboxylic acid.
[0418] Step 1: A mixture of 5-chloro-2-fluoro-4-(4,4,5,5 -tetramethyl- 1, 3, 2-dioxaborolan-2-yl)aniline (1.0 equiv), 1,1,1 -trifl uoro-2 -iodoethane (2.0 equiv), Pd2(dba)s (0.1 equiv), XantPhos (0.2 equiv), and CS2CO3 (3.00 equiv) in dioxane: H2O (10: 1, 0.1 M) was stirred at 80 °C overnight under nitrogen atmosphere. The mixture was cooled to rt and filtered. The filter cake was washed with EtOAc and the filtrates were partitioned between EtOAc and H2O. The phases were separated and the aqueous phase was back-extracted with EtOAc (2x). The combined organics were washed with water (2x), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with DCM / PE (20%) to afford 5-chloro-2-fluoro-4-(2,2,2-trifluoroethyl)aniline (46% yield) as yellow oil.
[0419] Step 2: The iodination of 5-chloro-2-fluoro-4-(2,2,2-trifluoroethyl)aniline from step 1 was carried out in similar fashion as described for the synthesis of Intermediate acid 20, step 2 which gave 3-chloro-6-fluoro-2-iodo-4-(2,2,2-trifluoroethyl)aniline (70% yield) as a yellow oil.
[0420] Step 3: The palladium-catalyzed in indole formation was carried out on 3-chloro-6-fluoro-2-iodo-4-(2,2,2-trifluoroethyl)aniline (from step 2) and pyruvic acid in similar fashion as described for the alternative synthesis of intermediate acid 1, step 2 which gave the title compound, Intermediate acid 23, as a yellow oil (28% yield).
[0421] Intermediate acid 24: Preparation of 5-cyclopropyl-4-(l-methyl-17 / -1.2,4-triazol-3-y 1)- 1 H-mdol e-2-carboxv lie acid.
[0422] Step 1: A mixture of ethyl 5-bromo-4-chloro-l-tosyl-177-indole-2-carboxylate (1.0 equiv), obtained as described for the synthesis of Intermediate acid 7, step 1, cyclopropylboronic acid (1.5 equiv), K2CO3 (2.5 equiv), and Pd(PPh?,)4 (0.1 equiv) in PhMe: H2O (4: 1, 0.08 M) was heated in a sealed reaction vessel at 100 °C for 23h. The mixture was cooled to rt and partitioned between EtOAc and H2O. The phases were separated and the organics were dried over MgSCh. filtered, and concentrated, silica gel chromatography (0% EtOAc in hexanes gradient to 20% EtOAc in hexanes) gave ethyl 4-chloro-5-cyclopropyl-l-tosyl-17 / -indole-2-carboxylate as a clear viscous oil (73% yield).
[0423] Step 2: The Stille coupling of ethyl 4-chloro-5-cyclopropyl-l-tosyl-177-indole-2-carboxylate from step 1 and 1-methyl-3-(tributylstannyl)-1H-1,2,4-triazole was performed in similar fashion as described for the synthesis of Intermediate acid 2 step 1, which gave ethyl 5-cy clopropyl-4-(l -methyl- \H- 1,2,4-triazol-3-yl)- 1 -tosyl- 177-indol e-2-carboxylate as a yellow oil (28% yield).
[0424] Step 3: The hydrolysis of ethyl 5-cyclopropyl-4-(l-methyl-177-l,2,4-triazol-3-yl)-l-tosyl-177-indole-2-carboxylate from step 2 was performed as described for the synthesis of Intermediate acid 1 step 3, with the exception that MeOH was substituted for EtOH, which gave the title compound (Intermediate acid 24) as a white powder (71% yield).
[0425] Intermediate acid 25: Preparation of 5-cyclopropyl-7-fluoro-4-(l-methyl-177-l,2,4-triazol-3-yl)- 177-in dole-2-carboxy lie acid.
[0426] Step 1: In a round-bottom flask equipped with a magnetic stirrer was combined Intermediate acid 20 (1.0 equiv) and PhMe (0.8 M). The flask was equipped with a reflux condenser and heated to 110 °C at which time Ar. X-dimethyl( di-lert-butoxy methyl )amme (3.0 equiv) was added dropwise. Stirring was continued at 110 °C for 30 min, then the reaction was cooled to rt and stirred for an additional 5 h. The reaction was diluted with MTBE and then washed sequentially with 10% aqueous sodium bicarbonate followed by 10% aqueous NaCl. The organics were dried over MgSCh. filtered, and the filtrate concentrated in vacuo to deliver tert-butyl 4-chloro-5-cyclopropyl-7-fluoro-l / 7-indole-2-carboxylate as a dark brown powder (84%).
[0427] Step 2: In a high-pressure flask equipped with a magnetic stirrer was combined tert-butyl 4-chloro-5-cyclopropyl-7-fluoro-17 -indole-2-carboxylate (1.0 equiv) from step 1, 1-methyl-3-(tributylstannyl)-17 -1.2.4-triazole (1.7 equiv), XPhos Pd G3 (0.2 equiv). and DMF (0.25 M). The flask was sealed, heated to 120 °C, and stirred overnight. After cooling to rt, the reaction was diluted with aqueous...
Claims
WHAT IS CLAIMED IS:
1. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the formula:Ring A is a heteroaryl;R1is independently halogen, -CX'3, -CHX'2, -CH2X1, -OCX's, -OCH2X1, -OCHX'2, -CN, -SOn1R1D, -SOv1NR1AR1B, -NR1CC(O)NR1AR1B, -N(O)m1, -NR1AR1B.-C(O)NR1AR1B, -OR1D, -SR1D, -NR1ASO2R1D, -NR1AC(O)R1C, -NR1AC(O)OR1C, -SF5, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R1substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;zl is an integer from 0 to 6;R2is hydrogen, halogen, -CX23, -CHX22. -CH2X2, -OCX23, -OCH2X2.-OCHX22, -CN, -SOn2R2D, -SOV2NR2AR2B, -NR2CC(O)NR2AR2B, -N(O)m2, -NR2AR2B, -C(O)NR2AR2B, -OR2D, -SR2D, -NR2ASO2R2D, -NR2AC(O)R2C, -NR2AC(O)OR2C, -SF5, -NS, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;R3, R4, and R5are independently hydrogen, halogen, -CCl3, -CBr3, -CFs, -CIs, -CHCI2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHC12, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -SO3H. -OSO3H. -SO2NH2, -NHNH2. -0NH2, -NHC(O)NHNH2, -NHC(O)NH2, -NO2. -NH2, -C(O)H, -C(O)OH, -CONH2, -OH, -SH, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -SF5, -N3, substituted or unsubstituted alky l, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;R6and R7are independently hydrogen, -CCl3, -CBn, -CF3, -CI3, -CH2CI, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2Cl, -OCH2Br, -OCH2F, -OCH2I, -OCHC12, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; R6and R7substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl;R1A, R1B, RIC, R1D, R2A, R2B, R2C, and R2Dare independently hydrogen, -CCI3, -CBr3, -CF3, -CI3, -CH2Cl, -CH2Br, -CH2F, -CH2I, -CHCl2, -CHBr2, -CHF2, -CHI2, -OCCl3, -OCBr3, -OCF3, -OCI3, -OCH2CI, -OCFbBr, -OCH2F, -OCH2I, -OCHC12, -OCHBr2, -OCHF2, -OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; R1Aand R1Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2Aand R2Bsubstituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;each X1and X2is independently -F, -Cl, -Br, or -I;nl and n2 are independently an integer from 0 to 4; andml, m2, vl, and v2 are independently 1 or 2.
2. The compound of claim 1, having the formula:
4. The compound of claim 1, wherein Ring A is a 5 to 10 membered heteroaryl.
5. The compound of claim 1, wherein Ring A is a 5 membered heteroaryl.
6. The compound of claim 1, wherein Ring A is pyrazolyl, triazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl. pyridazinyl, triazinyl, indazolyl, pyrazolopyridinyl, pyrrolotriazinyl, triazolopyridinyl, imidazopyrazinyl, pyrazolopyrazinyl, or purinyl.
8. The compound of claim 1, wherein R1is independently halogen, -CHX, -CN, -C(O)NR1AR1B, -OR1D, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
9. The compound of claim 1, wherein R1is independently -F, -Cl, -CHF2, -CN, -C(O)NH2, -OH, unsubstituted methyl, or unsubstituted cyclopropyl.
10. The compound of claim 1, wherein two R1substituents may optionally be joined to form a substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.1 11. The compound of claim 1, wherein zl is 1 or 2.1 12. The compound of claim 1, wherein zl is 0.
14. The compound of claim 1, wherein R2is hydrogen, halogen, -CX23, -CHX22, -CH2X2, -OCX23, -OCHX22, -CN, -OR2D, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
15. The compound of claim 1, wherein R2is hydrogen, -F, -Cl, -CF3, -CHF2, -OCF3, -OCHF2, -CN, unsubstituted methyl, unsubstituted isopropyl, unsubstituted methoxy, unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted oxetanyl.
16. The compound of claim 1, wherein R3is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
17. The compound of claim 1, wherein R3is hydrogen or -F.
18. The compound of claim 1, wherein R4is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
19. The compound of claim 1, wherein R4is hydrogen, -F, or -Cl.
20. The compound of claim 1, wherein R5is hydrogen, halogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C8 cycloalkyl.
21. The compound of claim 1, wherein R5is hydrogen, -F, -Cl, -I, or unsubstituted cyclopropyl.
22. The compound of claim 1, wherein R6is substituted or unsubstituted Ci-Cg alkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
23. The compound of claim 1, wherein R6is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted n-butyl, unsubstituted n-pentyl. unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted24. The compound of claim 1, wherein R7is substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
25. The compound of claim 1, wherein R7is -CD3, unsubstituted methyl,26. The compound of claim 1, wherein R6and R7substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
27. The compound of claim 1, wherein R6and R7substituents, together with the nitrogen atom to which they are bonded, are joined to form:
28. A pharmaceutical composition comprising the compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
29. A method of treating a SARM1 -associated disease in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt or solvate thereof.
30. The method of claim 29, wherein the SARM1-associated disease is a neurodegenerative disease.
31. The method of claim 30, wherein the neurodegenerative disease is Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, or chronic traumatic encephalopathy.
32. The method of claim 29, wherein the SARM1-associated disease is an inflammatory disease.
33. The method of claim 32, wherein the inflammatory disease is multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, or psoriasis.
34. The method of claim 29, wherein the SARM1 -associated disease is chemotherapy-induced peripheral neuropathy, diabetic neuropathy, Charcot-Marie-Tooth disease, stroke, chronic inflammatory demyelinating polyneuropathy. Guillain-Barre syndrome, hereditary neuropathy with liability to pressure palsy, nerve entrapment, nerve crust due to trauma, alcoholic neuropathy, motor endplate myopathy, a muscle-wasting disease, glaucoma, autosomal dominant optic atrophy, a mitochondrial disease, traumatic brain injury, a neurotrophic viral infection, or a bone disease.
35. The method of claim 34, wherein the Charcot-Marie-Tooth disease is CMT2 or CMTl.
36. The method of claim 29, wherein the SARM1-associated disease is a cancer.
37. A method of modulating SARM1 activity in a subject, said method comprising administering to the subject the compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt or solvate thereof.
